



# Immediate/Early vs. Delayed Invasive Strategy for Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: A Systematic Review and Meta-Analysis

Yanda Li<sup>1†</sup>, Zhenpeng Zhang<sup>1†</sup>, Xingjiang Xiong<sup>1†</sup>, William C. Cho<sup>2†</sup>, Dan Hu<sup>3</sup>, Yonghong Gao<sup>4</sup>, Hongcai Shang<sup>4\*</sup> and Yanwei Xing<sup>1\*</sup>

### **OPEN ACCESS**

### Edited by:

Jing-Yan Han, Peking University, China

#### Reviewed by:

Qiaobing Huang, Southern Medical University, China Bao-liang Sun, Taishan Medical University, China

#### \*Correspondence:

Hongcai Shang shanghongcai@126.com Yanwei Xing xingyanwei12345@163.com

<sup>†</sup>These authors have contributed equally to this work.

#### Specialty section:

This article was submitted to Vascular Physiology, a section of the journal Frontiers in Physiology

Received: 26 May 2017 Accepted: 08 November 2017 Published: 27 November 2017

#### Citation:

Li Y, Zhang Z, Xiong X, Cho WC, Hu D, Gao Y, Shang H and Xing Y (2017) Immediate/Early vs. Delayed Invasive Strategy for Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: A Systematic Review and Meta-Analysis. Front. Physiol. 8:952. doi: 10.3389/fphys.2017.00952 <sup>1</sup> Department of Cardiology, Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, China, <sup>2</sup> Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong, <sup>3</sup> Masonic Medical Research Laboratory, Utica, NY, United States, <sup>4</sup> The Key Laboratory of Chinese Internal Medicine of the Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China

Invasive coronary revascularization has been shown to improve prognoses in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS), but the optimal timing of intervention remains unclear. This meta-analysis is to evaluate the outcomes in immediate (< 2 h), early (< 24 h), and delayed invasive group and find out which is the optimal timing of intervention in NSTE-ACS patients. Studies were identified through electronic literature search of Medline, PubMed Central, Embase, the Cochrane Library, and CNKI. Data were extracted for populations, interventions, outcomes, and risk of bias. All-cause mortality was the pre-specified primary end point. The longest follow-up available in each study was chosen. The odds ratio (OR) with 95% CI was the effect measure. The fixed or random effect pooled measure was selected based on the heterogeneity test among studies. In the comparison between early and delayed intervention, we found that early intervention led to a statistical significant decrease in mortality rate (n = 6,624; OR 0.78, 95% CI: 0.61–0.99) and refractory ischemia (n= 6,127; OR 0.50, 95% CI: 0.40–0.62) and a non-significant decrease in myocardial infarction (MI), major bleeding and revascularization. In the analysis comparing immediate and delayed invasive approach, we found that immediate intervention significantly reduced major bleeding (n = 1,217; OR 0.46, 95% CI: 0.23-0.93) but led to a non-significant decrease in mortality rate, refractory ischemia and revascularization and a non-significant increase in MI. In conclusion, early invasive strategy may lead to a lower mortality rate and reduce the risk of refractory ischemia, while immediate invasive therapy shows a benefit in reducing the risk of major bleeding.

Keywords: non-ST-segment elevation acute coronary syndrome (NSTE-ACS), intervention, meta-analysis, major bleeding, invasive strategy, mortality rate

1

# INTRODUCTION

Mortality and incidence of recurrent myocardial infarction (MI) in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) are closely related to public health. Invasive coronary revascularization has been shown to improve outcomes in patients with NSTE-ACS (Mehta et al., 2005; Honnig et al., 2006; Fox et al., 2010), but the optimal timing of intervention remains unclear. The current European Society of Cardiology (ESC) guidelines recommend urgent (defined as <2 h) coronary intervention in patients with a very high risk, defined as: refractory angina, with associated heart failure, lifethreatening ventricular arrhythmias, or hemodynamic instability. What is more, early (ESC guidelines definition: <24 h) coronary intervention is recommended in patients with a Global Registry of Acute Coronary Events (GRACE) risk score above 140 or with high-risk features, which is defined as a relevant rise or fall in troponin or dynamic ST or T-wave changes (Hamm et al., 2011; Anderson et al., 2013).

However, at present, the optimal timing of routine invasive intervention is still controversial because of the conflicting reports of existed randomized controlled trials (RCTs) comparing early vs. delayed invasive approaches (Neumann et al., 2003; van't Hof et al., 2003; Mehta et al., 2009; Montalescot et al., 2009; Riezebos et al., 2009; Sciahbasi et al., 2010; Zhang et al., 2010; Thiele et al., 2012; Badings et al., 2013; Tekin et al., 2013; Liu et al., 2015; Reuter et al., 2015; Milosevic et al., 2016; Oosterwerff et al., 2016). Meta-analysis in recent years has also shown insufficient evidence either in favor of or against an early invasive strategy in the NSTE-ACS population (Navarese et al., 2011, 2013; Milasinovic et al., 2015; Jobs et al., 2017). In previous meta-analyses, mortality, MI, refractory ischemia (RI), major bleeding, and repeated revascularization were set as outcomes, and all the data were from the longest available follow-up (Navarese et al., 2011, 2013; Milasinovic et al., 2015; Jobs et al., 2017). Milasinovic D (Milasinovic et al., 2015), Eliano P (Navarese et al., 2011, 2013), and Jobs A (Jobs et al., 2017) found that compared with delayed invasive strategy, early invasive strategy might lead to a significant reduction in the occurrence of refractory ischemia, but conferred no benefit for other outcomes. One of the main limitations of the published meta-analysis was the small number of included studies. After literature retrieval, we updated four new studies (Liu et al., 2015; Reuter et al., 2015; Milosevic et al., 2016; Oosterwerff et al., 2016), hoping to gain a further conclusion with a larger sample size. In addition, by observing the data, we found that several studies used "<2 h" as the timing for immediate invasive therapy (Montalescot et al., 2009; Riezebos et al., 2009; Thiele et al., 2012; Milosevic et al., 2016; Oosterwerff et al., 2016). Therefore, we conducted an updated meta-analysis to assess outcomes between the immediate invasive group and the delayed invasive group.

# METHODS

This systematic review and meta-analysis was done in accordance with established methods (Higgins and Green, 2011) and the

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (Liberati et al., 2009).

## **Literature Search**

Studies were identified through a computerized literature search of Medline, PubMed Central, Embase, the Cochrane Library, and CNKI through May 2017. We also searched Clinical Trials Registries (https://clinicaltrials.gov/ and www.controlled-trials.com) for ongoing studies. To providing detailed descriptions of publication screening and reasons for exclusion, the PRISMA flow chart is shown in **Figure 1**.

# Search Strategy

The search strategy terms used were as follows: (Acute coronary syndrome OR unstable angina OR non-stemi OR non-ST elevation) AND (early OR delayed OR late OR immediate OR timing) AND (invasive intervention OR coronary angioplasty OR PCI) AND (randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR clinical trials as topic OR randomly OR trial). Reference lists of all included studies were manually reviewed by independent investigators.

# Selection Criteria

Studies were included if they enrolled patients with NSTE-ACS and randomly allocated patients to immediate/early invasive intervention or delayed invasive intervention. Immediate intervention was defined as coronary revascularization less than median 2 h after hospitalization or randomization. Early intervention was defined as coronary revascularization <24 h after enrollment. Delayed intervention was defined as pretreatment using standard medical therapy and subsequent revascularization 24 h or more after enrollment. Mortality rate should be listed as primary outcome. Studies about observational trials or comparing early/routine invasive with conservative/selective invasive strategy or without reliable outcome data were excluded.

# **Data Extraction**

Data were extracted on pre-specified forms by two independent investigators. Internal validity was independently appraised by two investigators, and divergences were resolved by discussion with a third investigator. Clinical characteristics, median time of catheterization and clinical outcomes at follow-up were extracted.

# **Quality Assessment**

The Cochrane Collaboration's tool for assessing risk of bias was used to assess the risk of bias (Higgins and Green, 2011) in the included studies, which is a domain-based evaluation of the following domains: random sequence generation (selection bias); allocation concealment (selection bias); blinding of participants and personnel (performance bias); blinding of outcome assessment (detection bias); incomplete outcome data (attrition bias); selective reporting (reporting bias); and other bias. Assessments for the risk of bias are provided in the risk of bias table for each study (**Figures 2, 3**).



## **Statistical Analysis**

Based on the different timing of the invasive procedures, we conducted two sets of meta-analyses: one in which early invasive therapy (<24 h) was compared with delayed invasive therapy, and another in which immediate invasive therapy (<2 h) was compared with delayed invasive therapy. Data were analyzed according to the intention-to-treat principle. Odds ratios (OR) and 95% confidence interval (CI) were used as summary statistics. The proportion of true variance in estimated effects among the included studies, as opposed to sampling error within studies, was calculated by the  $I^2$  statistic and statistical heterogeneity was considered substantial if  $I^2 > 75\%$ (Higgins and Green, 2011). Pooled ORs were calculated using the M-H random-effects model and fixed-effects model. Trial Sequential Analysis (TSA) was conducted to evaluate the sample size using TSA software version 0.9.5.9 beta (Supplementary Data Sheet 1). Publication bias was detected using funnel plots, with asymmetry suggesting possible publication bias. Publication bias was also assessed by Begg-test, Egger-test, and the funnel plots made using the STATA software version 12.0 (Figure 4) for the meta-analysis. Publication bias was considered existed if the P-value was <0.05. Sensitivity analyses were done by removing one study at a time from the metaanalysis for each of the outcomes using the STATA software version 12.0.

# RESULTS

## **Study and Patient Characteristics**

We screened 7,238 potentially relevant articles and excluded 7,201 of them after examining the titles and the abstracts (**Figure 1**). As a result of reviewing the full texts, we included a total of 14 studies of 13 RCTs; there was one study updated with a 5-year follow-up to the OPTIMA trial first reported in 2009 (Riezebos et al., 2009; Oosterwerff et al., 2016).

The RCTs enrolled 6,624 patients; 3,431 were randomly allocated to early invasive intervention and 3,193 to delayed invasive intervention. Trial characteristics were summarized in Table 1 and additional patient and trial characteristics were shown in Table 2. Baseline characteristics were wellbalanced within these studies, including age, female sex, diabetes, and ST-segment depression. The use of glycoprotein IIb/IIIa inhibitors did not differ significantly between different groups. The time of the intervention ranged from 0.5 to 24 h after randomization (early intervention) and 20.5 to 86 h (delayed intervention). The longest available follow-up for all events from the identified publications was recorded and it ranged from 30 days to 5 years. Most patients treated by coronary revascularization had percutaneous coronary intervention (PCI), and some had coronary artery bypass grafting (CABG). Patients randomly assigned to early vs. delayed



intervention were well-matched for demographic and clinical characteristics.

## **Risk of Bias**

Li et al

A review of the authors' judgments about each risk of bias item showed as percentages across all of the included RCTs. The

quality of the selected studies was assessed according to the Cochrane criteria (Figures 2, 3).

The RCTs were similar in their risk of bias. All were done according to the intention-to-treat principle; losses to followup were rare and described in detail. However, allocation concealment was not clearly addressed in six studies (**Figure 2**). Funnel plot for mortality, MI, and major bleeding revealed no apparent asymmetry, thus minimizing a potential risk of publication bias (**Figure 4**). Egger's regression test of publication bias was shown in **Table 3** and indicated little evidence of publication bias.

# Early (< 24 h) Invasive Therapy vs. Delayed Invasive Therapy

Individual and pooled ORs for mortality, MI, RI, major bleeding, and repeated revascularization are shown in Figure 5. Thirteen RCTs reported mortality, the results of the meta-analysis showed a statistically significant difference (n = 6,624; OR 0.78, 95% CI:  $0.61-0.99; I^2 = 0\%; P = 0.05;$  Figure 5A). Eleven RCTs reported MI, the results of the meta-analysis showed no statistically significant difference (n = 6,528; OR 0.83, 95% CI: 0.49–1.41;  $I^2 = 75\%$ ; P = 0.49; Figure 5B). Nine RCTs reported RI. The results of the meta-analysis showed that early invasive therapy was associated with a significant decrease in RI compared to the delayed invasive group (n = 6,127; OR 0.50, 95% CI: 0.40–0.62;  $I^2 = 49\%$ ; P < 0.00002; Figure 5C). Eleven RCTs reported major bleeding. The results of the meta-analysis showed no statistically significant difference (n = 6,439; OR 0.79, 95% CI: 0.61–1.02;  $I^2 = 0\%$ ; P = 0.07; Figure 5D). Six RCTs reported repeated revascularization. The results of the meta-analysis showed no statistically significant difference (n = 4,553; OR 0.53, 95% CI:  $0.23-1.21; I^2 = 87\%; P = 0.13;$  Figure 5E).

# Immediate (< 2 h) Invasive Therapy vs. Delayed Invasive Therapy

Individual and pooled ORs for mortality, MI, RI, major bleeding and repeated revascularization are shown in Figure 6. Four RCTs reported mortality. The results of the meta-analysis showed no statistically significant difference (n = 1,217; OR 0.92, 95% CI: 0.54–1.56;  $I^2 = 0\%$ ; P = 0.75; Figure 6A). Four RCTs reported MI. The results of the meta-analysis showed no statistically significant difference (n = 1,217; OR 1.47, 95% CI: 0.40–5.40;  $I^2 = 85\%$ ; P = 0.56; Figure 6B). We excluded individual studies to conduct sensitivity analyses to illustrate the heterogeneity, and the results showed a significant difference when the data from RIDDLE was excluded (95% CI 1.45–3.94; P = 0.0006;  $I^2 = 0\%$ ). Three RCTs reported RI. The results of the meta-analysis showed no statistically significant difference (n = 1,075; OR 0.42, 95% CI: 0.17–1.07;  $I^2 = 68\%$ ; P = 0.07; Figure 6C). Four RCTs reported major bleeding. The results of the meta-analysis showed that immediate invasive therapy could lead to a significant decrease in major bleeding compared to the delayed invasive group (n =1,217; OR 0.46, 95% CI:0.23–0.93;  $I^2 = 0\%$ ; P = 0.03; Figure 6D). Two RCTs reported repeated revascularization. The results of the meta-analysis showed no statistically significant difference (n =494; OR 0.58, 95% CI: 0.27–1.26;  $I^2 = 0\%$ ; P = 0.17; Figure 6E).



## **Sensitivity Analyses**

Sensitivity analyses were done by removing one study at a time from the meta-analysis for each of the outcomes (Supplementary Data Sheet 1). We found that in the comparison assessing mortality rate, MI, major bleeding and repeated revascularization between early and delayed invasive group (**Figure 5**), in the comparison assessing major bleeding and repeated revascularization between the immediate (< 2 h) and delayed invasive group (**Figure 6**), and in the comparison assessing major bleeding and repeated revascularization between the immediate (< 6 h) and delayed invasive group (**Figure 7**), exclusion of the data from several RCTs significantly skewed the results, indicating that these reports might be statistically unstable.

# **Trial Sequential Analysis**

TSA was done to evaluate the sample size and correct errors in the comparison assessing mortality rate between early (< 24 h) and delayed invasive therapy (**Figure 8**). The Lan-DeMets sequential monitoring boundary, which assumes a 6% control event rate and a 20% relative risk reduction with 80% power, has not been crossed, indicating that the cumulative evidence is inconclusive.

# DISCUSSION

We included 14 studies to analyze outcomes among patients with NSTE-ACS receiving immediate/early compared with delayed invasive approach and found that early intervention led to a statistical significant decrease in mortality rate and refractory ischemia and a non-significant decrease in MI, major bleeding and revascularization, while immediate invasive therapy was associated with a reduction in major bleeding.

# Added Value to Previous Meta-Analyses on the Same Topic

We updated four high-quality RCTs for the invasive strategy in NSTE-ACS. Although this was an updated meta-analysis, new results and content were found to provide evidence for the update

of the guidelines. Compared with published meta-analyses, we divided the definition of early intervention into immediate (<2h) and early (<24h), since timing of intervention would play an important role on clinical endpoints. We divided the meta-analysis in two components, one comparing early (< 24 h) vs. delayed (> 24 h) and the other one comparing immediate (< 2 h) vs. delayed, so as to seek more accurate conclusions on the impact of revascularization timing if NTSE-ACS on adverse events. Through comparison and analysis, we found early intervention led to a statistical significant decrease in mortality rate and immediate vs. delayed reduced the risk of major bleeding. Compared with other published (Rajpurohit et al., 2013), this result was first found in our article. Besides, in RCTs published before 2015, there was only the TIMACS trial, which used GRACE score as risk stratification. And the current guidelines recommend urgent coronary angiography in patients with a very high risk (GRACE score > 140), this is totally based on the conclusion of the TIMACS trial. However, in our updated analysis, we found the RIDDLE-NSTEMI trial also made a subgroup analysis, which showed no significant difference on the primary endpoint between patients in immediate and delayed invasive group, no matter the GRACE risk score was above 140 or below 140. We found another large sample study compared immediate and delayed intervention in NSTE-ACS patients: the IDEAL NSTEMI study (cinicaltrials.gov identifier NCT01638806; IDEAL NSTEMI, 2012), which will be completed in recent years, we will keep focus on this trial and update our conclusions at the first time.

# Early Invasive Strategy Might Reduce Mortality Rate

In the comparison assessing mortality rate between early and delayed invasive strategy, we found that early intervention led to a statistical significant decrease in mortality rate (n = 6,624; OR 0.78, 95% CI: 0.61–0.99;  $I^2 = 0\%$ ; P = 0.05; Figure 5A). This result was firstly found, the *P*-value of the assessment of mortality was 0.17 in 2011, 0.18 in 2013, 0.16 in 2015 and 0.0879 in 2016 (Navarese et al., 2011, 2013; Milasinovic et al., 2015; Jobs et al., 2017), and with the inclusion of four new



RCTS, a significant difference of the primary outcome appeared. Besides, the heterogeneity was low ( $I^2 = 0\%$ ), which increased the credibility of this result. However, the upper limit value of CI

was very close to 1 and P was the critical value, and according to the result of TSA, as the boundary line was not crossed, this conclusion was still inconclusive (**Figure 8**), to gain a stable

Study, year (References)	Median catheteri	time of zation, h	Patie	nts, <i>n</i>	Definitive	treatment (%)	Clinical outcomes at follow-up
	Early strategy	Delayed strategy	Early strategy	Delayed strategy	Early strategy	Delayed strategy	
ELISA, 2003 (van't Hof et al., 2003)	6	50	109	111	PCI:66 (60.5) CABG:15 (13.8) Medical:27 (24.7)	PCI:64 (57.7) CABG:21 (18.9) Medical:26 (23.4)	Death, MI, major bleeding, refractory ischemia at 1 month
ISAR-COOL, 2003 (Neumann et al., 2003)	2.4	86	203	207	PCI:143 (70.4) CABG:16 (7.9) Medical:44 (21.7)	PCI:133 (64.3) CABG:16 (7.7) Medical:58 (28.0)	Death, MI, major bleeding, refractory ischemia at 1 month
OPTIMA, 2009 (Riezebos et al., 2009) OPTIMA, 2016 (Oosterwerff et al.,	0.5	25	73	69	PCI:73 (100)	PCI:69 (100)	Death, MI, major bleeding, re-PCI at 1 month Death, MI, re-PCI at 5 years
2016) ABOARD, 2009 (Montalescot et al., 2009)	1.1	20.5	175	177	PCI:117 (66.9) CABG:16 (9.1) Medical:42 (24.0)	PCI:105 (59.3) CABG:17 (9.6) Medical:55 (31.1)	Death, MI, major bleeding, re-PCI, refractory ischemia at 1 month
TIMACS, 2009 (Mehta et al., 2009)	14	50	1593	1438	PCI:954 (59.9) CABG:255 (16.0) Medical:384 (24.1)	PCI:796 (55.4) CABG:219 (15.2) Medical:423 (29.4)	Death, MI, major bleeding, re-PCI, refractory ischemia at 6 months
Zhang et al., 2010 (Zhang et al., 2010)	9.3	49.9	446	369	PCI:314 (70.4) CABG:41 (9.2) Medical:91 (20.4)	PCI:252 (68.3) CABG:37 (10.1) Medical:80 (21.6)	Death, MI, major bleeding, re-PCI, refractory ischemia at 6 months
Sciahbasi, 2010 (Sciahbasi et al., 2010)	5	24	27	27	PCI:27 (100)	PCI:27 (100)	Death, re-PCI in 1 year
LIPSIA-NSTEMI, 2012 (Thiele et al., 2012)	1.1	67.2	200	200	PCI:151 (75.5) CABG:16 (8.0) Medical:33 (16.5)	PCI:114 (57.0) CABG:25 (12.5) Medical:61 (30.5)	Death, MI, refractory ischemia at 6 months, in-hospital major bleeding
ELISA3, 2013 (Badings et al., 2013)	2.6	54.9	269	265	PCI:180 (66.7) CABG:62 (23.2) Medical:27 (10.1)	PCI:164 (61.9) CABG:68 (25.7) Medical:33 (12.4)	Death, MI, major bleeding, refractory ischemia at 1 month
Tekin, 2013 (Tekin et al., 2013)	<24	24–72	69	62	PCI:69 (100)	PCI:62 (100)	Death, MI, LVEF, re-hospitalization at 3 months
RIDDLE, 2015 (Milosevic et al., 2016)	1.4	61	162	161	PCI:127 (78.4) CABG:20 (12.3) Medical:15 (9.3)	PCI:104 (65.0) CABG:38 (23.8) Medical:18 (11.2)	Death, MI, major bleeding, refractory ischemia at 1 year
SISCA , 2015 (Reuter et al., 2015)	2.8	20.9	83	87	PCI:45 (58) CABG:8 (10) Medical:25 (32)	PCI:45 (59) CABG:8 (11) Medical:23 (30)	Death, MI, major bleeding, re-PCI at 1 month
Liu et al., 2015 (Liu et al., 2015)	<12	12–24	22	20	PCI:22 (100)	PCI:20 (100)	Death, MI, major bleeding, re-PCI, refractory ischemia at 6 months

TABLE 1 | Timing of the invasive approach, definitive treatment, and clinical outcomes at follow-up for included RCTs comparing early and delayed strategies.

ABOARD, Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention; CABG, coronary artery bypass graft; ELISA, Early or Late Intervention in Unstable Angina; ISAR-COOL, Intracoronary Stenting with Antithrombotic Regimen Cooling Off; LIPSIA-NSTEMI, Leipzig Immediate vs. Early and Late Percutaneous Coronary Intervention Trial in Non–ST-Segment Elevation Myocardial Infarction; MI, myocardial infarction; PCI, percutaneous coronary intervention; RIDDLE, Randomized Study of Immediate vs. Delayed Invasive Intervention in Patients with Non-ST-segment Elevation Myocardial Infarction; SISCA, The Invasive Strategy in Acute Coronary Syndrome; TIMACS, Timing of Intervention in Acute Coronary Syndromes.

conclusion, further RCTs of large sample size and long-term follow-up are warranted.

The debate about the optimal timing of intervention for NSTE-ACS patients have lasted for years. On the one hand, an early approach may facilitate rapid diagnosis, earlier revascularization, and shorter hospital stays; on the other hand, patients may also take potential risks because of intervention on unstable plaques with fresh thrombus. Conversely, an optimal medical treatment for plaque passivation in delayed strategy may lead to benefits through following intervention on more stable plaques. Based on the results, it seems that early invasive strategy could provide a higher survival rate, and the potential benefit of delayed strategy might be offset. This may due to a higher risk for events while waiting for angiography.

# Immediate Invasive Strategy Might Reduce the Risk of Major Bleeding

In the analysis comparing immediate (within a median of 2 h after randomization) and delayed invasive approach, it is worth mentioning that immediate intervention significantly reduced

Study, year (References)	Mean	age, y	Female se	ж, <i>п</i> (%)	Diabetes	s, n (%)	ST-segm depression,	ent n (%)	3-vessel dise	ease, n (%)	Glycoprotein inhibitors, <i>r</i>	llb/Illa 1 (%)
	Early strategy	Delayed strategy	Early strategy	Early strategy	Early strategy	Delayed strategy	Early strategy	Delayed strategy	Early strategy	Delayed strategy	Early strategy	Delayed strategy
ELISA, 2003 (van't Hof et al., 2003)	63.0	65.0	79 (72.4)	76(68.4)	16(14.6)	16 (14.4)	NA	NA	31 (28.4)	33 (29.7)	0(0.0)	111 (100)
ISAR-COOL, 2003 (Neumann et al., 2003)	70.0	70.0	67 (33.0)	69 (33.3)	53 (26.1)	65 (31.4)	133 (65.5)	135 (65.2)	94 (46.3)	92 (44.4)	203 (100)	207 (100)
OPTIMA, 2009 (Riezebos et al., 2009)/2016 (Oostenwerff et al., 2016)	63.0	62.0	22 (30.0)	19 (26.0)	14 (19.2)	14 (20.3)	38(52.1)	36 (52.2)	10(13.7)	9 (13.0)	71 (97.3)	64 (92.8)
ABPARD, 2009 (Montalescot et al., 2009)	65.0	65.0	48 (27.4)	52 (29.4)	38(21.7)	57 (32.2)	122 (69.7)	136 (76.8)	32 (18.3)	44 (24.9)	114 (65.1)	101 (57.1)
<b>TIMACS, 2009 (</b> Mehta et al., 2009)	65.0	65.7	554 (34.8)	498 (34.6)	422 (26.5)	394 (27.7)	1282 (80.5)	1149(79.9)	272(171)	227 (15.8)	370 (23.2)	322 (22.4)
Zhang et al., 2010 (Zhang et al., 2010)	67.0	66.0	151 (33.9)	119 (32.2)	105 (23.5)	83 (22.5)	425 (95.3)	349 (94.6)	195 (43.7)	148(40.1)	82 (18.4)	79(21.4)
Sciahbasi, 2010 (Sciahbasi et al., 2010)	58.8	59.7	5 (18.5)	3(11.1)	7 (26.0)	5(18.5)	ЧN	AN	1 (4.0)	2 (7.0)	27 (100)	27 (100)
LIPSIA , 2012 (Thiele et al., 2012)	68.0	0.07	68 (34.0)	72 (36.0)	76(38.0)	64 (32.0)	122 (61.0)	124 (62.0)	59 (39.5)	63 (31.5)	195 (97.5)	197 (98.5)
ELISA3, 2013 (Badings et al., 2013)	72.1	71.8	82 (30.5)	91 (34.3)	64 (23.8)	54 (20.4)	ЧN	AN	89 (33.0)	70 (26.6)	AN	NA
<b>Tekin, 2013</b> (Tekin et al., 2013)	58.1	55.6	28 (40.6)	18(28.8)	22 (31.9)	28 (45.2)	56(81.2)	50 (80.6)	40(58.1)	35 (56.5)	AN	NA
RIDDLE, 2015 (Milosevic et al., 2016)	60.5	63.0	48 (29.6)	55 (34.2)	35(21.6)	52 (32.3)	125(77.7)	130 (80.7)	57 (35.2)	65 (40.6)	152 (93.8)	146 (90.7)
<b>SISCA</b> , 2015 (Reuter et al., 2015)	63.9	66.5	25 (30.0)	23 (27.0)	35 (42.0)	28 (33.0)	63 (76.0)	65 (76.0)	NA	NA	83(100)	87 (100)
Liu et al., 2015 (Liu et al., 2015)	80.4	80.3	11 (50.0)	7 (35.0)	11 (50.0)	11 (55.0)	Ч	NA	7 (31.8)	9 (45.0)	NA	AN

TABLE 2 | Clinical Characteristics of RCTs in Meta-analysis.

Outcomes	Std. Eff.	Coef.	Std. Err.	t	<b>P</b> > t	[95%	6 CI]
Mortality (<24 h)	Slope	0.0462328	0.1642426	0.28	0.784	-0.3197226	-0.4121883
	Bias	0.4695734	0.3770398	1.25	0.241	-0.3705238	1.30967
MI (<24 h)	Slope	0.0716176	0.3936487	0.18	0.860	-0.8188776	0.9621127
	Bias	0.3686991	1.099424	0.34	0.745	-2.118372	2.85577
Major bleeding (<24 h)	Slope	-0.0947393	0.181002	-0.52	0.613	-0.5041942	0.3147156
	Bias	0.7986756	0.4080998	1.96	0.082	-0.1245103	1.721861

**TABLE 3** | Egger's test of publication bias for mortality, MI, and major bleeding.

Coef, coefficient; Std. Eff, Standard Effect; Std. Err, Standard Error.

major bleeding and the heterogeneity was low (n = 1,217; OR 0.46, 95% CI:0.23–0.93;  $I^2 = 0\%$ ; P = 0.03; **Figure 6D**). As to further specify the influence of the timing on major bleeding, we conducted a new analysis including trials in which intervention was done within 6 h after randomization and the result showed a non-significant decrease in the risk of major bleeding (n = 1,797; OR 0.58, 95% CI: 0.33–1.01;  $I^2 = 0\%$ ; P = 0.06; **Figure 7**).

In addition, we found that immediate approach led to a nonsignificant decrease in mortality rate, RI and revascularization and a non-significant increase in MI. Combing with the data in the comparison between early and delayed intervention group, this result suggested that the risk of major bleeding might increase with the delay of the timing of intervention: intervention within 2 h significantly reduced the risk of major bleeding; in the case of intervention within 6 h, there was a weak tendency toward less bleeding (*P*-value = 0.06); when assessing the effect of intervention within 24 h, this advantage had almost disappeared (the *P*-value was 0.55).

In the four trails defining "<2 h" as immediate, antithrombotic pre-treatment was approximate: dual antiplatelet therapy with aspirin and clopidogrel was used, along with heparin. Abciximab (0.25 mg/kg followed by an infusion of 10 µg/min for 12h) was used in OPTIMA and ABOARD, while tirofiban (25 µg/kg followed by continuous infusion of 0.15 µg/kg/min for 24 h) was used in LIPSIA. However, part of the description of the dose of medication was not very clear, some drugs were used "for at least 24 h" and some were "left to the discretion of the investigators." The risk of major bleeding decreased in immediate invasive group, one possible reason was that if the intervention was immediately started, the dosage of drugs that may cause bleeding complications (such as heparin and Glycoprotein IIb/IIIa inhibitors) was considerably reduced, as these antiplatelet drugs would be used throughout the waiting period of surgery.

The common sources of non-access site-related bleeding after PCI included gastrointestinal bleeding, cerebral hemorrhage, retroperitoneal hematoma, etc. (Kwok et al., 2015). Gastrointestinal bleeding had been associated with an in-hospital mortality of  $\leq$ 10% (Abbas et al., 2005; Nikolsky et al., 2009). The onset of MI might cause fear, anxiety and pain, stimulate the sympathetic nerves and increase catecholamine secretion, constrict gastric mucosal vessel and lead to acute gastric mucosal bleeding. So, another possible reason was that the waiting time of patients in immediate intervention group was shortened, the remission of MI symptoms relieved the patients' anxiety and physical pain, thus lessening the risk of stress ulcer, which perhaps was the main cause of gastrointestinal bleeding after intervention (Tetsuya et al., 2011).

## **Other Outcomes**

In the comparison between early (within 24 h after randomization) and delayed intervention, we found that early intervention led to no significant decrease in MI, major bleeding, and revascularization and a statistically significant decrease in refractory ischemia, which was supported by previous pooled meta-analysis.

## **Risk Stratification**

The current guidelines recommend urgent (ESC guidelines definition: < 2 h) coronary intervention in patients with a very high risk, defined as: refractory angina, with associated heart failure, life-threatening ventricular arrhythmias, or hemodynamic instability. In addition, early (ESC guidelines definition: <24 h) coronary angiography is recommended to patients whose GRACE risk score is above 140 or with high-risk features, defined as a relevant rise or fall in troponin or dynamic ST or T-wave changes (Hamm et al., 2011; Levine et al., 2011). However, only 2 of 14 trails used GRACE score as risk stratification. One was the TIMACS trial, the other was the RIDDLE-NSTEMI trial which was updated by our meta-analysis. In the TIMACS trial, In patients with a GRACE risk score of more than 140 (the highest risk), the mortality rate was 13.9% in the early-intervention group, as compared with 21.0% in the delayed-intervention group, a reduction of 35.0% in the early-intervention group (HR, 0.65; 95% CI, 0.48–0.89; P = 0.006). However, among patients with a score of 140 or less (a combination of the low risk), no significant difference between the two groups was found (7.6 vs. 6.7%; hazard ratio, 1.12; 95% CI, 0.81–1.56; P = 0.48; P = 0.01 for heterogeneity; Mehta et al., 2009). However, in the RIDDLE-NSTEMI trial, there was no significant difference on the primary endpoint between patients in immediate and delayed invasive group, no matter the GRACE risk score was above 140 or below 140 (Milosevic et al., 2016). Although these two articles used the same hierarchical approach with GRACE score, the RIDDLE-NSTEMI trial and the TIMACS trial reached different conclusions. In the RIDDLE-NSTEMI trial, there was

۸								
	Mortality (21h)							
~	Mortanty (<2411)	early	delaye	d		Odds Ratio		Odds Ratio
	Study or Subgroup	Events Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fixed, 95% Cl
	2003 ELISA	3 109	5	111	3.2%	0.60 [0.14, 2.57]		
	2003 ISAR-COOL	0 203	3	207	2.3%	0.14 [0.01, 2.80]	+	
	2009 ABOARD	5 175	2	177	1.3%	2.57 [0.49, 13.45]		
	2009 TIMACS	76 1593	85	1438	57.2%	0.80 [0.58, 1.10]		
	2010 SCIANBASI	0 27	0	27		Not estimable		
	2010 Zhang et al.	16 446	12	369	8.5%	1.11 [0.52, 2.37]		
	2012 LIPSIA	9 200	13	200	8.3%	0.68 [0.28, 1.62]		
	2013 ELISA3	3 269	3	265	2.0%	0.98 [0.20, 4.92]		
	2013 Tekin et al.	0 69	3	62	2.5%	0.12 [0.01, 2.42]	-	
	2015 Liu et al.	0 22	5	20	3.8%	0.06 [0.00, 1.22]	•	-
	2015 RIDDLE	8 162	9	161	5.8%	0.88 [0.33, 2.33]		
	2015 SISCA	1 83	2	87	1.3%	0.52 [0.05, 5.83]		
	2016 OPTIMA	6 73	6	69	3.8%	0.94 [0.29, 3.07]		
	T-4-1 (05% OI)	0404		0400	400.00/	0 70 10 04 0 001		
	Total (95% CI)	3431		3193	100.0%	0.78 [0.61, 0.99]		•
	Total events	127	148					
	Heterogeneity: Chi <sup>2</sup> =	8.90, df = 11 (P =	0.63); 1*	= 0%			0.01	0.1 1 10 100
-	lest for overall effect:	Z = 2.00 (P = 0.0)	5)					Favours early Favours delayed
в	Myocardial Infarcti	$\operatorname{ion}(<24h)$	delayer			Odda Patia		Odda Patia
	Study or Subgroup	Evente Total	Evente	I Fotal I	Noight	M H Bandom 95% (	4	M-H Bandom 95% Cl
			Events	444	0 EN	4 45 10 45 4 70	-	M-H, Randolli, 95% Ci
	2003 ELISA	12 202	21	207	0.0%	1.45 [0.45, 4.75]		
	2003 ISAR-COUL	12 203	21	477	11.5%	0.56 [0.27, 1.16]		
	2009 ABOARD	76 1500	0	1439	14 00/	0.83 (0.60 4 44		-
	2009 TIMACS	22 440	40	360	12 0%	0.05 [0.00, 1.14		
	2010 Zhang et al.	23 440	40	209	12.9%	2 27 1 21 / 20		
	2012 LIF SIA 2013 ELISAS	5 260	2	265	6 1%	2 49 10 48 12 05		
	2013 Tekin et al	2 60	2	62	6 4%	0 18 10 04 0 05		
		4 162	16	161	8 9%	0 23 10 07 0 70		
	2015 SISCA	1 82	10	87	4 5%	0.09 10.01 0.76	_	
	2010 0100A	R 73	10	60	4 4 10/	8 37 11 02 68 70		
	2010 OF TIMA	5 /5	1	00	4.470	0.01 [1.02, 00.79]		
	Total (95% CI)	3382	2	3146	100.0%	0.83 [0.49. 1.41]		+
	Total events	187	210					
	Heterogeneity: Tau <sup>2</sup> =	0.50; Chi <sup>2</sup> = 40.71	, df = 10 (	P < 0.0	001); l <sup>2</sup> =	75%	H-	
	Test for overall effect:	Z = 0.69 (P = 0.49	))				0.01	0.1 1 10 100
С	Refractory Ischem	ia (<24h)						Favours early Favours delayed
•	Refluctory ischem	early	delaye	d		Odds Ratio		Odds Ratio
	Study or Subgroup	Events Total	Events	Total	Weight	M-H, Fixed, 95% C		M-H, Fixed, 95% Cl
	2003 ELISA	13 109	14	111	5.1%	0.94 [0.42, 2.10]		
	2003 ISAR-COOL	27 203	39	207	14.1%	0.66 [0.39, 1.13]		
	2009 ABOARD	21 175	33	177	12.1%	0.60 [0.33, 1.08]		
	2009 TIMACS	16 1593	47	1438	20.5%	0.30 [0.17, 0.53]		
	2010 Zhang et al.	26 446	29	369	12.6%	0.73 [0.42, 1.26]		
	0	20 440	20					
	2012 LIPSIA	0 200	20	200	8.6%	0.02 [0.00, 0.37]	•	
	2012 LIPSIA 2013 ELISA3	0 200 20 269	20 33	200 265	8.6% 12.9%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01]	•••	
	2012 LIPSIA 2013 ELISA3 2015 Liu et al.	0 200 20 269 3 22	20 33 10	200 265 20	8.6% 12.9% 3.8%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.16 [0.04, 0.71]	•	
	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE	0 200 20 269 3 22 16 162	20 33 10 27	200 265 20 161	8.6% 12.9% 3.8% 10.3%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.16 [0.04, 0.71] 0.54 [0.28, 1.05]		
	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE	0 200 20 269 3 22 16 162	20 33 10 27	200 265 20 161	8.6% 12.9% 3.8% 10.3%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.16 [0.04, 0.71] 0.54 [0.28, 1.05]		
	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI)	0 200 20 269 3 22 16 162 <b>3179</b>	20 33 10 27	200 265 20 161 <b>2948</b>	8.6% 12.9% 3.8% 10.3% <b>100.0%</b>	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.16 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62]	•	
	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE <b>Total (95% CI)</b> Total events	20 440 0 200 20 269 3 22 16 162 3179 142	20 33 10 27 252	200 265 20 161 <b>2948</b>	8.6% 12.9% 3.8% 10.3% <b>100.0%</b>	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.16 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62]		•
	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup>	20 440 0 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P =	20 33 10 27 252 252 : 0.05);   <sup>2</sup> :	200 265 20 161 <b>2948</b> = 49%	8.6% 12.9% 3.8% 10.3%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.16 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62]	0.01	
	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect:	0 200 0 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = Z = 6.21 (P < 0.0	20 33 10 27 252 : 0.05); l <sup>2</sup> : 0001)	200 265 20 161 <b>2948</b> = 49%	8.6% 12.9% 3.8% 10.3%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.16 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62]	0.01	0.1 1 10 100 Favours delayed
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: ChP = Test for overall effect: Major Bleeding (<	0 200 0 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = Z = 6.21 (P < 0.0 (24h)	20 33 10 27 252 0.05); l <sup>2</sup> 0001)	200 265 20 161 <b>2948</b> = 49%	8.6% 12.9% 3.8% 10.3%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.16 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62]	0.01	0.1 1 10 100 Favours early Favours delayed
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Major Bleeding (<	0 200 0 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = Z = 6.21 (P < 0.0 (24h) early	20 20 33 10 27 252 : 0.05); l <sup>2</sup> : 0001) delaye	200 265 20 161 <b>2948</b> = 49%	8.6% 12.9% 3.8% 10.3%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.16 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] Odds Ratio	0.01	0.1 1 10 100 Favours early Favours delayed
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u>	0 200 0 200 20 269 3 22 16 167 3179 142 15.72, df = 8 (P = Z = 6.21 (P < 0.0 (24h) early Events Total	20 20 33 10 27 252 50.05); l <sup>2</sup> 0001) delaye Events	200 265 20 161 <b>2948</b> = 49% d Total	8.6% 12.9% 3.8% 10.3% 100.0% Weight	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.61 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] Odds Ratio M-H, Fixed, 95% CI	0.01	0.1 1 10 100 Favours early Favours delayed Odds Ratio M-H, Fixed. 95% Cl
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% Cl) Total events Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA	0 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = Z = 6.21 (P < 0.0 (24h) early Events Total 9 109	20 20 33 30 27 252 50.05);   <sup>2</sup> 50.05);   <sup>2</sup> 0001) delaye <u>Events</u> 15	200 265 20 161 <b>2948</b> = 49% d Total 111	8.6% 12.9% 3.8% 10.3% 100.0% Weight 10.4%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] Odds Ratio <u>M-H. Fixed, 95% CI</u> 0.58 [0.24, 1.38]	0.01	0.1 1 10 100 Favours early Favours delayed Odds Ratio M-H. Fixed. 95% Cl
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL	20 440 0 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = Z = 6.21 (P < 0.0 (24h) early <u>early</u> 9 109 6 203	20 20 33 10 27 252 0005);   <sup>2</sup> 0005);   <sup>2</sup> 0001) delaye Events 15 8	200 265 20 161 <b>2948</b> = 49% d Total 111 207	8.6% 12.9% 3.8% 10.3% 100.0% <u>Weight</u> 10.4% 5.9%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] Odds Ratio M-H. Fixed, 95% CI 0.58 [0.24, 1.38] 0.76 [0.26, 2.22]	0.01	Odds Ratio
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL 2009 ABOARD	$\begin{array}{c} 20 & -470 \\ 0 & 200 \\ 20 & 269 \\ 3 & 22 \\ 16 & 162 \\ \hline 3179 \\ 142 \\ 15.72, df = 8 (P = \\ Z = 6.21 (P < 0.0 \\ c24h) \\ early \\ \hline Events \ Total \\ 9 & 109 \\ 6 & 203 \\ 7 & 175 \end{array}$	20 20 33 10 27 252 : 0.05);   <sup>2</sup> : 0001) delaye <u>Events</u> 15 8 12	200 265 20 161 <b>2948</b> = 49% d <u>Total</u> 111 207 177	8.6% 12.9% 3.8% 10.3% 100.0% <u>Weight</u> 10.4% 5.9% 8.7%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.61 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] Odds Ratio M-H, Fixed, 95% CI 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49]	0.01	O.1 1 10 100 Favours delayed Odds Ratio M-H, Fixed, 95% Cl
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total events Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL 2009 ABOARD 2009 OPTIMA	20 440 20 200 20 269 3 22 16 162 15.72, df = 8 (P = 2 = 6.21 (P < 0.0 (24h) <u>early</u> <u>Events Total</u> 9 109 6 203 7 175 3 73	20 20 33 10 27 252 0.005);   <sup>2</sup> : 0001) delaye <u>Events</u> 15 8 12 6	200 265 20 161 <b>2948</b> = 49% d Total 111 207 177 69	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% Une for the second sec	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] Odds Ratio M-H. Fixed, 95% CI 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87]	0.01	0.1 1 10 100 Favours early Favours delayed Odds Ratio M-H. Fixed. 95% Cl
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL 2009 ABOARD 2009 OPTIMA 2009 ITMACS	20 440 0 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = Z = 6.21 (P < 0.0 (24h) early 9 109 6 203 7 175 3 73 49 1593	20 20 33 10 27 252 0005); l <sup>2</sup> : 0001) <b>delaye</b> <u>Events</u> 15 8 12 6 50	200 265 20 161 <b>2948</b> = 49% d Total 111 207 177 69 1438	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% <u>Weight</u> 10.4% 5.9% 8.7% 4.5% 38.9%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.61 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] Odds Ratio <u>M-H. Fixed, 95% CI</u> 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32]	0.01	Olds Ratio
D	2012 LIPSIA 2013 ELISA3 2013 ELISA3 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL 2009 ABOARD 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA	$\begin{array}{ccccc} & 20 & 440 \\ 0 & 200 & 269 \\ 3 & 22 \\ 16 & 162 \\ \hline & & & & & \\ 142 & 15.72, df = 8 (P = \\ Z = 6.21 (P < 0.0 \\ c24h) \\ \hline & & & & & \\ early \\ \hline & & & & & \\ Fvents & Total \\ 9 & 109 \\ 6 & 203 \\ 7 & 175 \\ 3 & 73 \\ 49 & 1593 \\ 3 & 446 \end{array}$	20 20 33 10 27 252 0.05);   <sup>2</sup> = 0001) delaye Events 15 8 12 6 50 2	200 265 20 161 <b>2948</b> = 49% d Total 111 207 177 69 1438 369	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% <u>Weight</u> 10.4% 5.9% 8.7% 4.5% 38.9% 1.7%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48]	0.01	0.1 1 10 100 Favours delayed Odds Ratio M-H. Fixed. 95% Cl
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total events Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Major Bleeding (< 2003 ELISA 2003 ISAR-COOL 2009 ABOARD 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2000 DTIMACS 2010 Zhang et al. 2012 LIPSIA	20 440 0 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = 2 2 = 6.21 (P < 0.0 :24h) early Events Total 9 109 6 203 7 175 3 73 49 1593 3 446 1 200	20 33 10 27 252 50.05);   <sup>2</sup> 0001) delaye Events 15 8 8 12 6 50 2 2	200 265 20 161 <b>2948</b> = 49% d Total 111 207 177 69 1438 369 200	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0% 5.9% 8.7% 4.5% 38.9% 1.7% 1.5%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.24, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.45 [0.11, 1.87] 0.45 [0.21, 7.48] 0.50 [0.04, 5.53]	0.01	Odds Ratio M-H. Fixed, 95% Cl
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ELISA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 DIMACS 2010 Zhang et al. 2011 ZLIPSIA 2013 ELISA3	$\begin{array}{c} 20 & +40 \\ 0 & 200 \\ 20 & 269 \\ 3 & 22 \\ 16 & 162 \\ \hline & 3179 \\ 142 \\ 15.72, df = 8 (P = 2 \\ 2 = 6.21 (P < 0.0 \\ c24h) \\ \hline & early \\ \hline early \\ \hline events \ Total \\ 9 & 109 \\ 6 & 203 \\ 7 & 175 \\ 3 & 73 \\ 49 & 1593 \\ 3 & 446 \\ 1 & 200 \\ 32 & 269 \end{array}$	20 33 10 27 252 0.05); l <sup>2</sup> 0001) delaye Events 15 8 12 6 50 2 2 2 29	200 265 20 161 <b>2948</b> <b>d</b> <b>Total</b> 111 207 177 69 1438 369 200 265	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0% 100.0% 8.7% 4.5% 38.9% 1.5% 19.6%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.61 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 1.24 [0.21, 7.48] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87]	0.01	Olds Ratio
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% Cl) Total events Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2010 Zhang et al. 2012 LIPSIA 2013 ELISA3 2015 Liu et al.	20 440 0 200 20 269 3 22 16 162 <b>3179</b> <b>142</b> <b>15.72</b> , <i>df</i> = 8 (P = 2 <b>5.72</b> , <i>df</i> = 8 (P = 2 <b>5.72</b> , <i>df</i> = 8 (P = 2 <b>6.21</b> (P < 0.0 (24h) <b>9</b> 109 6 203 7 175 3 73 49 1593 3 446 1 200 32 269 0 22	20 33 10 27 252 0.05); l <sup>2</sup> : 0001) <b>delaye</b> <b>Events</b> 8 12 6 50 2 2 2 9 5	200 265 20 161 <b>2948</b> <b>49%</b> <b>d</b> <b>Total</b> 111 207 177 69 1438 369 200 265 20	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 10.4% 5.9% 8.7% 4.5% 38.9% 1.7% 1.5% 19.6% 4.3%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.24, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.06 [0.00, 1.22]	0.01	O.1 1 10 100 Favours delayed Odds Ratio M-H, Fixed. 95% Cl
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total events Heterogeneity: Chi <sup>a</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL 2009 ABOARD 2009 TIMACS 2010 Zhang et al. 2013 ELISA3 2013 ELISA3 2015 Liu et al. 2015 Liu et al.	20 440 20 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = 2 = 6.21 (P < 0.0 :24h) 9 109 6 203 7 175 3 73 49 1593 3 446 1 200 32 269 0 22 1 162	20 33 10 27 252 0.005);   <sup>2</sup> 0001) delaye Events 15 8 12 6 50 2 2 9 5 5	200 265 20 161 <b>2948</b> d <b>Total</b> 111 207 177 69 1438 369 200 265 20 161	8.6% 12.9% 3.8% 10.3% <b>100.0%</b> <b>Weight</b> 10.4% 5.9% 8.7% 4.5% 38.9% 1.7% 1.5% 19.6% 4.3% 3.8%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.32, 1.01] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.45 [0.11, 1.87] 0.45 [0.21, 1.48] 1.24 [0.21, 7.48] 0.50 [0.04, 1.53] 1.10 [0.64, 1.87] 0.66 [0.00, 1.22] 0.19 [0.02, 1.58]	0.01	Odds Ratio M-H. Fixed, 95% Cl
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ELISA 2009 ABOARD 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2010 Zhang et al. 2015 Liu et al. 2015 RIDDLE 2015 SISCA	$\begin{array}{c} 20 & +40 \\ 0 & 200 \\ 20 & 269 \\ 3 & 22 \\ 16 & 162 \\ \hline & 3179 \\ 142 \\ 15.72, df = 8 (P = 2 \\ 2 & 6.21 (P < 0.0 \\ c24h) \\ \hline & early \\ \hline early \\ early \\ \hline early \\ early \\ \hline early \\ early \\ 15.73 \\ 15.93 \\ 3 & 73 \\ 15.93 \\ 3 & 446 \\ 1 & 200 \\ 32 & 269 \\ 0 & 22 \\ 1 & 162 \\ 2 & 83 \end{array}$	20 33 10 27 252 0.005); I <sup>a</sup> 0001) <b>delaye</b> Events 15 8 12 6 50 2 2 29 5 5 5 1	200 265 20 161 <b>2948</b> <b>d</b> <b>Total</b> 111 207 1438 369 200 265 20 161 87	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0% 8.7% 4.5% 38.9% 1.5% 19.6% 4.3% 3.8% 0.7%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.61 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.77 [0.22, 1.49] 0.45 [0.11, 1.87] 1.24 [0.21, 7.48] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.66 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 23.87]	0.01	Olds Ratio
D	2012 LIPSIA 2013 ELISA3 2013 ELISA3 2015 RIDDLE Total (95% Cl) Total events Heterogeneity: Ch <sup>a</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2010 DAng et al. 2012 LIPSIA 2013 ELISA3 2015 RIDDLE 2015 SISCA	20 440 20 200 20 269 3 22 16 162 3179 142 15.7.2.6.21 (P < 0.0 (24h) early Events Total 9 109 6 203 7 175 3 73 49 1593 3 446 1 200 32 269 0 22 1 62 2 83	20 33 10 27 252 0.05);   <sup>2</sup> 0.05);   <sup>2</sup> 0.05);   <sup>2</sup> 0.001) delaye Events 15 8 12 6 50 2 2 9 5 5 1	200 265 20 161 2948 = 49% d Total 111 207 177 9 438 369 200 265 20 161 87	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0% 100.0% 8.7% 4.5% 38.9% 1.7% 1.5% 19.6% 4.3% 3.8% 0.7%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.32, 1.01] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.56 [0.04, 5.53] 1.10 [0.64, 1.87] 0.69 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 23.87]	0.01	O.1 1 10 100 Favours delayed Odds Ratio M-H, Fixed, 95% Cl
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total events Heterogeneity: Chi <sup>p</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL 2009 ABOARD 2009 TIMACS 2010 Zhang et al. 2013 ELISA3 2013 ELISA3 2015 Liu et al. 2013 ELISA3 2015 Liu et al. 2015 SISCA	20 440 20 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = 2 2 = 6.21 (P < 0.0 -24h) early Events Total 9 109 6 203 7 175 3 73 49 1593 3 446 1 200 32 269 0 22 1 162 2 83 3335	20 33 30 27 252 20.05); I <sup>#</sup> : 0001) delaye Events 8 12 6 50 2 2 29 5 5 5 1	200 265 20 161 <b>2948</b> = 49% d <b>Total</b> 111 207 177 69 200 265 20 161 369 200 161 87 3104	8.6% 12.9% 3.8% 10.3% 100.0% 100.0%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.32, 1.01] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.57 [0.22, 1.49] 1.24 [0.21, 7.48] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.66 [0.00, 1.22] 0.51 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02]	0.01	Odds Ratio M-H. Fixed, 95% Cl
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ELISA 2009 ABOARD 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2010 Zhang et al. 2017 LIPSIA 2015 RIDDLE 2015 SISCA Total (95% CI) Total events	$\begin{array}{c} 20 & -400\\ 0 & 200\\ 20 & 269\\ 3 & 22\\ 16 & 162\\ \hline & 3179\\ 142\\ 15.72, df = 8 (P = 2\\ 2 & 6.21 (P < 0.0\\ c24h)\\ \hline & early\\ early\\ \hline early\\ earl$	20 33 10 252 (0.05);   <sup>2</sup> = 0001) delaye Events 15 8 12 6 50 2 2 29 5 5 1 135	200 265 20 161 <b>2948</b> <b>49%</b> d <b>Total</b> 111 207 69 1438 369 200 265 20 161 87 <b>3104</b>	8.6% 12.9% 3.8% 10.3% 100.0% 100.0%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.40, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 1.24 [0.21, 7.48] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.06 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02]	0.01	Olds Ratio
D	2012 LIPSIA 2013 ELISA3 2013 ELISA3 2015 ELIDA3 2015 RIDDLE Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2010 Zhang et al. 2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 SISCA Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> =	20 440 20 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = 2 24.1) early Events Total 9 109 6 203 7 175 3 73 49 1593 3 446 1 200 32 269 0 22 1 162 2 83 335 113 8.77, df = 10 (P =	20 33 100 27 252 50.05);   <sup>2</sup> 0001) <b>delaye</b> <b>Events</b> 15 8 12 6 50 2 2 9 5 5 1 1 35 5 1 1 35 5,   <sup>2</sup>	200 265 20 161 2948 = 49% d Total 111 207 177 69 200 265 20 161 87 3104 \$	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% <b>Weight</b> 10.4% 5.9% 4.5% 38.9% 1.7% 1.5% 1.5% 1.5% 3.8% 0.7% <b>100.0%</b>	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.32, 1.01] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.56 [0.04, 1.53] 1.10 [0.64, 1.87] 0.69 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02]	0.01	Olds Ratio
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total events Heterogeneity: Chi <sup>p</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL 2009 ABOARD 2009 TIMACS 2010 Zhang et al. 2013 ELISA3 2013 ELISA3 2013 ELISA3 2015 Liu et al. 2013 ELISA3 2015 Liu et al. 2015 SISCA Total (95% CI) Total events Heterogeneity: Chi <sup>p</sup> = Test for overall effect:	20 440 20 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = 2 2 = 6.21 (P < 0.0 24h) early Events Total 9 109 6 203 7 175 3 73 49 1593 3 446 1 200 32 269 0 22 1 162 2 83 3335 113 8.77, df = 10 (P = 2 2 = 1.83 (P = 0.0	20 30 31 30 27 252 20.05);   <sup>2</sup> = 0001) delaye Events 15 8 12 6 50 2 2 9 5 5 1 135 0.55);   <sup>2</sup> = 7 1 135 0.55);   <sup>2</sup> = 7 1 1 1 1 1 1 1 1 1 1 1 1 1	200 265 20 161 <b>2948</b> <b>d</b> <b>Total</b> 111 207 177 69 200 265 200 265 200 161 87 <b>3104</b>	8.6% 12.9% 13.8% 10.3% 100.0% 100.0%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.40, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.19 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02]	0.01	Odds Ratio M-H. Fixed, 95% Cl Odds Ratio M-H. Fixed, 95% Cl
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Ch <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ELISA 2003 ISAR-COOL 2009 ABOARD 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2010 Zhang et al. 2017 LIPSIA 2015 RIDDLE 2015 RIDDLE 2015 RISCA Total (95% CI) Total events Heterogeneity: Ch <sup>2</sup> = 1 Test for overal effect: Repeated Revascul	200 440 200 269 3 222 16 162 3179 142 15.72, df = 8 (P = 0.0 (24h) early Events Total 9 109 6 203 7 175 3 73 49 1593 3 446 1 200 32 269 0 22 1 162 2 83 3335 113 8.77, df = 10 (P = 0.0 arization (<2	20 30 31 10 27 252 0001) delaye Events 15 8 12 6 50 0 2 2 9 5 5 1 1 135 0.55;   <sup>2</sup> = 0002 2 2 9 5 5 1 1 10 10 10 10 10 10 10 10	200 265 20 161 2948 = 49% d Total 111 207 1438 369 200 161 87 3104 • 0%	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.16 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 1.24 [0.21, 7.48] 0.50 [0.04, 1.53] 1.10 [0.64, 1.87] 0.06 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02]	0.01	Odds Ratio M-H. Fixed. 95% CI
D	2012 LIPSIA 2013 ELISA3 2013 ELISA3 2015 ELIDA3 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2015 LISA3 2012 LIPSIA 2013 ELISA3 2015 RIDDLE 2015 RIDDLE 2015 RISCA Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Repeated Revascul	20 440 20 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = 2 (24h) early Events Total 9 109 6 203 7 175 3 73 49 1593 3 446 1 200 32 269 0 22 1 162 2 83 335 113 8.77, df = 10 (P = 2 2 = 1.83 (P = 0.0 cited and the second	20 20 20 20 252 20.05);   <sup>2</sup> 0001) delaye Events 15 8 12 6 50 2 29 5 5 1 135 0.55);   <sup>2</sup> 7 4 h) delaye	200 265 20 161 2948 = 49% d Total 111 207 177 77 79 1438 369 200 265 20 161 87 3104 - 0%	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.32, 1.01] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.56 [0.04, 1.53] 1.10 [0.64, 1.53] 1.01 [0.64, 1.87] 0.79 [0.61, 1.02] 0.45 Ratio	0.01	Odds Ratio M-H, Fixed, 95% Cl 0.1 1 10 100 Favours delayed 0.1 1 10 100 Favours delayed 0.1 1 10 100 Favours delayed 0.1 1 0 100 Favours delayed
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total 95% CI) Total events Heterogeneity: Chi <sup>a</sup> = Test for overall effect 2003 ELISA 2003 ISAR-COOL 2009 TIMACS 2010 Zhang et al. 2010 Zhang et al. 2015 RIDDLE 2015 RIDDLE 2015 RIDDLE 2015 SISCA Total 95% CI) Total events Heterogeneity: Chi <sup>a</sup> = Test for overall effect: ReDeated Revascul	20 440 20 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = 2 2 = 6.21 (P < 0.0 :24h) early Events Total 9 109 6 203 7 175 3 73 49 1593 3 446 1 200 32 269 0 22 1 162 2 83 3335 113 8.77, df = 10 (P = 2 2 = 1.83 (P = 0.0 arization (<2 early Events Total	20 20 20 20 252 252 20.05);   <sup>2</sup> = 0001) delaye Events 15 8 12 6 50 2 2 29 5 5 1 135 0.55);   <sup>2</sup> = 7 4h) delaye Events	2000 2665 200 161 2948 d Total 111 207 69 1438 369 200 265 200 161 377 69 1438 369 200 161 111 207 69 1438 369 200 161 177 69 1438 369 200 161 177 69 1438 369 200 161 177 69 1438 369 200 161 177 69 1438 369 200 161 177 69 1438 369 200 161 177 69 1438 369 200 161 177 177 69 1438 369 200 161 177 177 69 1438 369 200 205 200 161 177 177 169 169 167 177 177 177 177 1438 369 200 200 200 201 161 207 161 177 169 167 167 177 177 177 177 177 177	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0% 8.7% 4.5% 5.9% 19.6% 4.3% 0.7% 100.0%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.40, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.06 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02] Odds Ratio M-H, Random, 95% CO	0.01	Odds Ratio M-H. Fixed. 95% Cl 0.1 1 10 100 Favours early Favours delayed 0.1 1 0 100 Favours early Favours delayed 0.1 1 0 100 Favours early Favours delayed Odds Ratio M-H. Random, 95% Cl
D	2012 LIPSIA 2013 ELISA3 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Ch <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ELISA 2003 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2010 Zhang et al. 2017 LIPSIA 2015 RIDDLE 2015 RIDDLE 2015 RIDDLE 2015 SISCA Total (95% CI) Total events Heterogeneity: Ch <sup>2</sup> = : Test for overall effect: ReDeated Revascula	$\begin{array}{c} 0 & 200 \\ 0 & 200 \\ 200 & 269 \\ 3 & 22 \\ 16 & 162 \\ \hline & & & & & & \\ \hline & & & & & \\ \hline & & & &$	20 30 31 10 27 252 20.05);   <sup>2</sup> = 0001) delaye Events 15 8 12 6 50 2 2 9 9 5 5 1 1 135 0.55);   <sup>2</sup> = 7) 4h) delayee Events 1 10 10 15 8 12 15 15 15 15 16 15 15 15 16 15 16 15 16 15 16 15 16 15 16 15 16 15 16 15 16 15 16 15 16 15 16 15 16 15 16 16 15 16 16 16 16 16 16 16 16 16 16	2000 265 20 161 <b>2948</b> d <b>Total</b> 111 107 207 177 69 200 265 20 161 87 <b>3104</b> 0%	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0% 4.5% 3.8% 0.7% 1.5% 4.3% 3.8% 0.7% 100.0% Meight 18.7%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.16 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 1.24 [0.21, 7.48] 0.50 [0.04, 1.53] 1.10 [0.64, 1.87] 0.06 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 2.387] 0.79 [0.61, 1.02] Odds Ratio M-H. Random. <u>95% C</u> 0.59 [0.21, 1.67]	0.01	Odds Ratio M-H. Fixed. 95% Cl Odds Ratio M-H. Fixed. 95% Cl Odds Ratio M-H. Random. 95% Cl
D	2012 LIPSIA 2013 ELISA3 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total 95% CI) Total events Heterogeneity: Ch <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2010 Dang et al. 2012 LIPSIA 2013 ELISA3 2013 ELISA3 2015 RIDDLE 2015 RIDDLE 2015 RISCA Total 95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 1 Test for overall effect: ReDeated Revascul: <u>Study or Subgroup</u> 2009 ABOARD 2009 TIMACS	20 440 20 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = 2 2 = 6.21 (P < 0.0 (24h) 9 109 6 203 7 175 3 73 49 1593 3 494 1 200 32 269 0 22 1 162 2 83 3335 113 8.77, df = 10 (P = 2 2 = 1.38 (P = 0.0 arization (<2 early Events Total 6 175 139 1593	20 33 100 27 252 20.05);   <sup>2</sup> 0001) delaye Events 15 8 12 6 50 2 2 2 9 5 1 135 0.55);   <sup>2</sup> 7 4h) delaye Events 7 10 10 122	2000 2665 20 161 <b>2948</b> <b>d</b> <b>Total</b> 111 207 69 200 2655 200 161 87 <b>3104</b> 60%	8.6% 12.9% 12.9% 10.3% 100.0% 100.0% 4.5% 38.9% 4.5% 38.9% 4.5% 38.9% 1.7% 1.7% 1.7% 1.7% 1.6% 0.7% 16.7% 22.2%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.32, 1.01] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.69 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02] Odds Ratio MHH. Random. 95% C 0.59 [0.21, 1.67] 1.03 [0.80, 1.33]	0.01 0.01	Odds Ratio M-H. Fixed, 95% Cl Odds Ratio M-H. Fixed, 95% Cl Odds Ratio M-H. Random, 95% Cl
D	2012 LIPSIA 2013 ELISA3 2013 ELISA3 2015 ELIDE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ELISA 2003 BAR-COOL 2009 ABOARD 2009 OPTIMA 2009 OPTIMA 2010 Zhang et al. 2015 RIDDLE 2015 RIDDLE 2015 RISCA Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 1 Test for overall effect: Redeated Revascul: <u>Study or Subgroup</u> 2009 ABOARD 2009 DTIMACS 2010 Zhang et al.	20 440 0 200 20 269 3 22 16 162 3179 142 2 6.21 (P < 0.0 :24h) early Events Total 9 109 6 203 7 175 3 73 49 1593 3 446 1 200 32 269 0 22 1 162 2 83 3355 113 8.77, df = 10 (P = 0.0 arization (<2 early Events Total 6 175 139 1593 53 446	20 30 31 10 27 252 2005);   <sup>2</sup> = 0001) delaye Events 5 5 1 1 135 2 2 9 5 5 1 1 135 5 5 1 1 135 5 5 1 1 10 10 10 10 15 8 12 6 50 5 5 1 1 15 12 16 10 10 10 10 10 15 8 12 6 50 5 5 1 1 1 15 12 12 12 12 12 12 12 12 12 12	2000 2655 20 161 <b>2948</b> d <b>Total</b> 111 207 177 6 9 438 369 200 265 20 161 87 3104 50% 4 50%	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0% 8.7% 4.5% 4.5% 4.3% 3.8% 4.3% 4.3% 4.3% 1.5% 10.6% 4.3% 4.3% 1.5% 1.5% 1.5% 4.3% 4.3% 4.3% 2.2% 4.2% 4.3% 2.2% 2.2% 2.2% 2.2% 2.2% 2.2% 2.2% 2	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.66 [0.04, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.66 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02] Odds Ratio MH. Random. 95% C 0.59 [0.21, 1.67] 1.03 [0.80, 1.33] 1.58 [0.98, 2.54]	0.01	Odds Ratio M-H. Fixed. 95% Cl 0.1 1 0 100 Favours delayed Odds Ratio M-H. Fixed. 95% Cl 0.1 1 0 100 Favours delayed 0.1 1 0 100 Favours delayed Odds Ratio M-H. Random, 95% Cl
D	2012 LIPSIA 2013 ELISA3 2013 ELISA3 2015 ELIDA3 2015 RIDDLE Total (95% CI) Total events Heterogeneity: CriP = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ELISA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2015 ELISA3 2015 Liu et al. 2015 RIDDLE 2015 SISCA Total (95% CI) Total events Heterogeneity: CriP = : Test for overall effect: Repeated Revascul <u>Study or Subgroup</u> 2009 ABOARD 2009 TIMACS 2010 Zhang et al. 2015 Liu et al.	20 440 0 200 20 269 3 22 16 162 15.72, df = 8 (P = 1 2 = 6.21 (P < 0.0 (24h) early Events Total 9 109 6 203 7 175 3 73 49 1593 3 446 1 200 32 269 0 22 1 162 2 83 8.77, df = 10 (P = 2 3335 113 8.77, df = 10 (P = 2 2 = 1.83 (P = 0.0 arization (<2 early Events Total 6 175 139 1593 5 3 446 1 22	20 20 20 20 20 252 20.05);   <sup>2</sup> 0001) delayee Events 15 8 12 6 50 2 2 9 5 1 135 0.55);   <sup>2</sup> 5 1 135 0.55);   <sup>2</sup> 4 h) delayee Events 1 1 1 2 2 9 5 1 1 1 1 1 1 1 1 1 1 1 1 1	2000 265 20 161 <b>2948</b> <b>d</b> <b>Total</b> 111 207 177 177 177 1438 369 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> 20 <b>5</b> <b>5</b> 20 <b>5</b> <b>5</b> 20 <b>5</b> <b>5</b> 20 <b>5</b> <b>5</b> <b>6</b> <b>5</b> <b>1</b> <b>1</b> <b>1</b> <b>1</b> <b>1</b> <b>1</b> <b>1</b> <b>1</b>	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0% 8.7% 4.5% 38.9% 3.8% 0.7% 1.5% 1.5% 1.5% 1.6% 2.2% 100.0%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.65 [0.34, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.24, 1.38] 1.24 [0.21, 7.48] 0.50 [0.04, 1.53] 1.24 [0.21, 7.48] 0.50 [0.04, 1.53] 1.10 [0.64, 1.87] 0.66 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02] Odds Ratio M:H. Random. 95% C 0.59 [0.24, 1.67] 1.03 [0.80, 1.33] 1.58 [0.98, 2.54] 0.43 [0.04, 5.13]	0.01	Odds Ratio M-H. Random, 95% Cl Odds Ratio M-H. Random, 95% Cl
D	2012 LIPSIA 2013 ELISA3 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total 95% CI) Total events Heterogeneity: Ch <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2010 Zhang et al. 2011 Zhang et al. 2015 SISCA Total 95% CI) Total events Heterogeneity: Ch <sup>2</sup> = 1 Test for overall effect: ReDeated Revascul 2009 ABOARD 2009 TIMACS 2010 Zhang et al. 2010 Zhang et al. 2015 Liu et al. 2015 Liu et al.	20 440 20 200 20 269 3 22 16 162 3179 142 15.72, df = 8 (P = 2 2 = 6.21 (P < 0.0 2.24h) 9 109 6 203 7 175 3 73 49 1593 3 449 159 3 49 6 10 2 83 8.77, df = 10 (P = 2 3335 113 8.77, df = 10 (P = 2 2 83 8.77, df = 10 (P = 2 2 83 8.77, df = 10 (P = 2 2 83 8.77, df = 10 (P = 2 5 83 1 22 5 83 1 22 5 83 1 22 5 83 1 22 5 83 1 22 1 12 2 83 1 22 1 22 1 23 1 22 1 23 1 22 1 23 1 22 1 23 1 23 1 23 1 23 1 23 1 23 1 23 1 23 1 23 1 24 1 25 1 2	200 33 100 27 252 0.0.5);   <sup>3</sup> 0001) delaye Events 15 8 12 2 6 5 5 1 135 0.55);   <sup>2</sup> 7 4h) delaye Events 7 4h) 122 2 9 5 5 1 1 135 0.55;   <sup>2</sup> 2 2 9 5 5 1 1 135 0.55;   <sup>2</sup> 2 2 2 9 5 5 1 1 135 0.55;   <sup>2</sup> 2 2 2 9 5 5 1 1 135 0.55;   <sup>2</sup> 2 2 2 9 5 5 1 1 135 0.55;   <sup>2</sup> 2 2 2 9 5 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2000 265 20 161 <b>2948</b> <b>d</b> <b>Total</b> 111 207 177 177 1438 369 200 265 200 161 87 <b>3104</b> <b>6</b> <b>6</b> <b>6</b> <b>7</b> <b>7</b> <b>7</b> <b>7</b> <b>7</b> <b>7</b> <b>7</b> <b>7</b>	8.6% 12.9% 12.9% 10.3% 100.0% 100.0% 100.0% 4.5% 38.9% 4.5% 38.9% 4.5% 1.7% 1.7% 1.7% 1.6.% 2.2% 21.1%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.40, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.59 [0.21, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02] 0dds Ratio M-H. Random95% C 0.59 [0.21, 1.63] 1.58 [0.98, 2.54] 0.43 [0.04, 5.13] 1.58 [0.98, 2.54] 0.43 [0.04, 5.13] 0.56 [0.02, 0.15] 0.59 [0.22, 1.58] 0.59 [0.22, 1.58] 0.59 [0.22, 1.58] 0.59 [0.22, 1.58] 0.59 [0.22, 1.58] 0.59 [0.22, 1.58] 0.59 [0.22, 0.55] 0.59 [0.52, 0.55]	0.01	Odds Ratio M-H. Fixed. 95% Cl 0.1 1 0 100 Favours early Favours delayed 0.1 1 0 100 Favours early Favours delayed 0.1 1 0 100 Favours early Favours delayed 0dds Ratio M-H. Random. 95% Cl
D	$\begin{array}{c} 2012 \ \text{LIPSIA}\\ 2013 \ \text{ELISA3}\\ 2013 \ \text{ELISA3}\\ 2013 \ \text{ELISA3}\\ 2015 \ \text{RIDDLE}\\ \hline \\ \textbf{Total events}\\ \textbf{Heterogeneity: Chi^2 = 1}\\ \textbf{Total events}\\ \textbf{Heterogeneity: Chi^2 = 1}\\ \textbf{Total events}\\ \textbf{Total events}\\ \textbf{Constrained}\\ 2003 \ \text{ELISA}\\ 2003 \ \text{ELISA}\\ 2003 \ \text{ELISA}\\ 2009 \ \text{OPTIMA}\\ 2009 \ \text{OPTIMACS}\\ 2010 \ \text{Zhang et al.}\\ 2015 \ \text{RIDDLE}\\ 2015 \ \text{RIDDLE}\\ 2015 \ \text{RISCA}\\ \hline \\ \textbf{Total events}\\ \textbf{Heterogeneity: Chi^2 = 1}\\ \textbf{Test for overall effect:}\\ \textbf{Rebeated Revascul}\\ \hline \\ \hline \\ \textbf{Study or Subgroup}\\ 2009 \ \text{RIMACS}\\ 2010 \ \text{Zhang et al.}\\ 2015 \ \text{SISCA}\\ \hline \\ \hline \\ \hline \\ \textbf{Study or Subgroup}\\ 2009 \ \text{ABOARD}\\ 2009 \ \text{TIMACS}\\ 2010 \ \text{Zhang et al.}\\ 2015 \ \text{SISCA}\\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \hline \\ \ \\ \hline \\ \hline \\ \hline $	$\begin{array}{c} 0 & 200\\ 0 & 200\\ 20 & 269\\ 3 & 22\\ 16 & 162\\ \hline & 142\\ 15.72, df = 8 (P = 1\\ early \\ early \\ early \\ early \\ early \\ 175\\ 3 & 73\\ 49 & 1593\\ 3 & 446\\ 1 & 200\\ 32 & 269\\ 0 & 22\\ 1 & 162\\ 2 & 83\\ \hline & 3335\\ 1 & 169\\ 2 & 169\\ 2 & 169\\ 2 & 169\\ 2 & 169\\ 2 & 169\\ 2 & 169\\ 1 & 200\\ 2 & 169\\ 1 & 200\\ 2 & 169\\ 2 & 169\\ 2 & 169\\ 2 & 169\\ 2 & 169\\ 2 & 169\\ 2 & 169\\ 2 & 169\\ 2 & 169\\ 2 & 169\\ 2 & 169\\ 1 & 200\\ 2 & 169\\$	20 33 10 27 252 0.05);   <sup>2</sup> = 0001) delaye Events 6 50 2 2 9 5 5 1 1 135;   <sup>2</sup> = 0,55);   <sup>2</sup> = 7) delaye Events 5 5 1 1 135;   <sup>2</sup> = 0,55;   <sup>2</sup> = 1 1 135;   <sup>2</sup> = 1 1 15 8 12 2 9 5 5 1 1 1 1 15 8 12 2 2 9 5 5 1 1 1 1 1 1 1 1 1 1 1 1 1	2000 2655 20 161 <b>2948</b> <b>d</b> <b>Total</b> 1111 2077 1777 69 1438 369 200 2655 200 161 87 <b>3104</b> <b>•</b> <b>•</b> <b>•</b> <b>•</b> <b>•</b> <b>•</b> <b>•</b> <b>•</b> <b>•</b> <b>•</b>	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0% 8.7% 4.5% 4.5% 1.5% 100.0% 10.6% 10.0%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.34, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.69 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02] 0.49 [0.61, 1.02] 0.59 [0.21, 1.67] 1.03 [0.80, 1.33] 1.58 [0.98, 2.54] 0.43 [0.04, 5.13] 1.58 [0.98, 2.54] 0.43 [0.04, 5.13] 0.55 [0.22, 1.68] 0.59 [0.21, 1.67] 1.03 [0.80, 1.33] 1.58 [0.98, 2.54] 0.43 [0.04, 5.13] 0.55 [0.22, 1.68] 0.55 [0.21, 1.67] 0.56 [0.07, 1.81] 0.55 [0.21, 1.67] 0.56 [0.17, 1.81] 0.56 [0.17, 1.81] 0.56 [0.17, 1.81]	0.01 0.01	Odds Ratio M-H. Fixed. 95% Cl 0.1 1 0 100 Favours delayed 0.1 1 0 100 Favours delayed 0.1 1 0 100 Favours delayed Odds Ratio M-H. Random. 95% Cl
D	2012 LIPSIA 2013 ELISA3 2013 ELISA3 2015 ELIDA3 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ELISA 2003 ISAR-COOL 2009 ABOARD 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2015 Chi 2015 2010 Zhang et al. 2015 RIDDLE 2015 SISCA Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Repeated Revascul <u>Study or Subgroup</u> 2009 ABOARD 2009 TIMACS 2010 Zhang et al. 2015 SISCA	20 440 0 200 20 269 3 22 16 162 15.72, df = 8 (P = 1 2 = 6.21 (P < 0.0 (24h) early Events Total 9 109 6 203 7 175 3 73 49 1593 3 446 1 200 32 269 0 22 1 162 2 83 8.77, df = 10 (P = 2 3355 113 8.77, df = 10 (P = 2 2 = 1.83 (P = 0.0 arization (<2 early Events Total 6 175 139 1593 5 3 446 1 22 5 83 5 73	20 20 33 10 0 27 252 20.05);   <sup>2</sup> 0001) delaye Events 15 8 12 6 50 2 29 5 1 135 0.55);   <sup>2</sup> ( <sup>2</sup> ) 6 5 1 1 135 0.55);   <sup>2</sup> ( <sup>2</sup> ) 4 1 1 1 1 2 2 9 5 1 1 1 1 1 1 1 1 1 1 1 1 1	2000 265 20 161 <b>2948</b> <b>d</b> <b>Total</b> 111 207 69 200 161 87 309 200 265 20 161 87 3104 <b>5</b> <b>6</b> <b>1</b> <b>1</b> <b>1</b> <b>1</b> <b>1</b> <b>1</b> <b>1</b> <b>1</b>	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0% 10.4% 5.9% 4.5% 3.8% 0.7% 1.5% 1.5% 1.7% 1.5% 100.0% 100.0%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.65 [0.34, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.50 [0.04, 1.53] 1.10 [0.64, 1.87] 0.66 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02] Odds Ratio M-H. Random. 95% C 0.59 [0.24, 1.67] 1.03 [0.80, 1.33] 1.58 [0.98, 2.54] 0.43 [0.04, 5.13] 0.56 [0.17, 1.81] 0.56 [0.17, 1.81]	0.01	Odds Ratio M-H. Fixed. 95% Cl Odds Ratio M-H. Random, 95% Cl Odds Ratio M-H. Random, 95% Cl
D	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Ch <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ISAR-COOL 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2010 Zhang et al. 2012 LIPSIA 2013 ELISA3 2013 ELISA3 2013 ELISA3 2015 SISCA Total (95% CI) Total events Heterogeneity: Ch <sup>2</sup> = i Test for overall effect: ReDeated Revascul <u>Study or Subgroup</u> 2009 ABOARD 2009 TIMACS 2010 Zhang et al. 2015 SISCA 2010 Zhang et al. 2015 SISCA 2010 Zhang et al. 2015 SISCA 2010 Zhang et al. 2015 SISCA 2010 Chang et al. 2015 SISCA 2016 OPTIMA	$\begin{array}{c} \textbf{20} & \textbf{-40} \\ 0 & 200 \\ 0 & 200 \\ 20 & 269 \\ 3 & 22 \\ 16 & 162 \\ \textbf{3179} \\ \textbf{142} \\ \textbf{15.72, df = 8 (P = 1 \\ 2 & 6.21 (P < 0.0 \\ -24h) \\ \textbf{early} \\ \textbf{Events Total} \\ \textbf{9} & 109 \\ 6 & 203 \\ 7 & 175 \\ \textbf{3} & 73 \\ \textbf{49} & 1593 \\ \textbf{3335} \\ \textbf{1133} \\ \textbf{346} \\ \textbf{1} & 200 \\ 32 & 269 \\ 0 & 22 \\ \textbf{1} & 162 \\ 2 & 83 \\ \textbf{3335} \\ \textbf{335} \\ \textbf{35} \\ 35$	200 33 100 27 252 0.05);  * 0001) delaye Events 15 8 12 6 50 2 2 29 5 5 1 135 0.55);  * 2 7 4 h) delaye Events 7 4 h) 122 29 2 47 8	2000 265 20 161 2948 49% d Total 111 207 69 200 265 20 161 87 3104 60% 1777 438 369 200 265 20 161 87 3104 265 20 1438 87 69 20 50 50 20 50 50 50 50 50 50 50 50 50 50 50 50 50	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0% 8.7% 4.5% 5.9% 8.7% 4.5% 19.6% 4.3% 0.7% 100.0% 100.0%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.56 [0.40, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.50 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02] 0dds Ratio M-H. Random. 95% C 0.59 [0.21, 1.67] 1.53 [0.80, 1.33] 1.58 [0.98, 2.54] 0.43 [0.04, 5.13] 0.56 [0.17, 1.81] 0.53 [0.22, 1.12]	0.01	Odds Ratio M-H, Fixed, 95% Cl 0.1 1 0 100 Favours delayed 0.1 1 0 100 Favours delayed 0.1 1 0 100 Favours delayed Odds Ratio M-H, Random, 95% Cl 0
E	2012 LIPSIA 2013 ELISA3 2013 ELISA3 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total events Heterogeneity: Ch <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ELISA 2003 ELISA 2003 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2013 ELISA3 2015 RIDDLE 2015 RIDDLE 2015 RIDDLE 2015 RISCA Total (95% CI) Total events Heterogeneity: Ch <sup>2</sup> = 1 Test for overall effect: Rebeated Revascul <u>Study or Subgroup</u> 2009 ABOARD 2009 TIMACS 2010 Zhang et al. 2015 SISCA 2015 SISCA 2016 DepTIMA	$\begin{array}{c} 0 & 200\\ 0 & 200\\ 20 & 269\\ 3 & 22\\ 16 & 162\\ \hline & 142\\ 15.72, df = 8 (P = 1\\ z = 6.21 (P < 0.0\\ (24h)\\ early\\ early\\ \hline events \ Total\\ 9 & 109\\ 6 & 203\\ 7 & 175\\ 3 & 73\\ 49 & 1593\\ 3 & 446\\ 1 & 200\\ 32 & 269\\ 0 & 22\\ 1 & 162\\ 2 & 83\\ 3 & 346\\ 1 & 200\\ 32 & 269\\ 0 & 22\\ 1 & 162\\ 2 & 83\\ 3 & 3335\\ 133\\ 446\\ 1 & 200\\ 2 & 83\\ 3 & 3335\\ 133\\ 3 & 446\\ 1 & 200\\ 2 & 83\\ 1 & 120\\ 2 & 101\\ 1 & 101\\ $	20 33 10 27 252 0.05);   <sup>2</sup> 0001) <b>delaye</b> <b>Events</b> 15 8 12 6 50 0 2 2 9 9 5 5 1 1 135 0.55);   <sup>2</sup> 7 4 1 122 29 2 4 1 10 122 2 2 2 3 5 5 1 1 10 15 8 12 10 15 8 12 10 15 15 15 15 10 15 15 10 10 10 15 10 10 10 10 10 10 10 10 10 10	2000 265 20 161 2948 d Total 111 207 1438 369 200 161 177 1438 369 200 161 177 177 69 200 161 177 1438 3704 1177 177 69 200 60 87 3104 177 177 69 87 3104 177 177 177 69 87 3104 1177 1177 1177 1177 1178 200 69 200 60 87 200 60 87 200 60 87 200 60 87 200 60 87 200 60 87 200 60 87 200 60 87 200 60 87 200 60 87 200 60 87 200 60 87 200 60 87 200 60 87 200 60 87 200 60 87 200 60 87 200 60 87 60 87 200 60 87 60 87 60 87 60 87 60 87 60 87 60 87 60 87 60 87 60 87 60 87 60 87 60 87 60 87 60 60 87 87 87 87 87 87 87 87 87 87	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% Weight 1.5% 4.5% 1.5% 10.0% Weight 18.6% 10.0%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.65 [0.40, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.50 [0.04, 1.53] 1.10 [0.64, 1.87] 0.06 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02] 0.49 [0.21, 1.67] 1.03 [0.80, 2.54] 0.59 [0.21, 1.67] 1.03 [0.80, 2.54] 0.59 [0.21, 1.67] 1.03 [0.80, 2.54] 0.43 [0.04, 5.13] 1.58 [0.98, 2.54] 0.43 [0.04, 5.13] 0.55 [0.27, 1.81] 0.53 [0.23, 1.21]	0.01	Odds Ratio M-H, Fixed, 95% Cl 0.1 1 00 Favours delayed 0.1 1 00 0.1 1 00 Favours delayed 0.1 1 0 100 Favours delayed 0.1 1 0 100 Favours delayed 0.1 1 0 100 Favours delayed 0.1 1 0 100 Favours delayed
D	2012 LIPSIA 2013 ELISA3 2013 ELISA3 2013 ELISA3 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ELISA 2003 ISAR-COOL 2009 ABOARD 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2012 LIPSIA 2013 ELISA3 2013 ELISA3 2015 Liu et al. 2015 SISCA Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 1 Test for overall effect: Repeated Revascul <u>Study or Subgroup</u> 2009 ABOARD 2009 TIMACS 2010 Zhang et al. 2015 SISCA 2010 Zhang et al. 2015 SISCA	$\begin{array}{c} \textbf{20}  \textbf{400} \\ \textbf{0}  \textbf{200} \\ \textbf{200}  \textbf{269} \\ \textbf{3}  \textbf{222} \\ \textbf{16}  \textbf{162} \\ \textbf{142} \\ \textbf{15.72}, \textbf{df} = \textbf{8} \ (\textbf{P} = \textbf{1} \\ \textbf{2} = \textbf{6.21} \ (\textbf{P} < \textbf{0.0} \\ \textbf{300} \\ \textbf{300} \\ \textbf{7}  \textbf{175} \\ \textbf{3}  \textbf{73} \\ \textbf{49}  \textbf{1593} \\ \textbf{37}  \textbf{33} \\ \textbf{49}  \textbf{1593} \\ \textbf{333}  \textbf{3466} \\ \textbf{1}  \textbf{200} \\ \textbf{32}  \textbf{269} \\ \textbf{0}  \textbf{32}  \textbf{269} \\ \textbf{3335} \\ \textbf{133} \\ \textbf{8.77}, \textbf{df} = \textbf{10} \ (\textbf{P} = \textbf{2} \\ \textbf{2}  \textbf{83} \\ \textbf{3355} \\ \textbf{113} \\ \textbf{8.77}, \textbf{df} = \textbf{10} \ (\textbf{P} = \textbf{2} \\ \textbf{2}  \textbf{83} \\ \textbf{3355} \\ \textbf{113} \\ \textbf{8.77}, \textbf{df} = \textbf{10} \ (\textbf{P} = \textbf{2} \\ \textbf{2}  \textbf{83} \\ \textbf{3355} \\ \textbf{133} \\ \textbf{8.77}, \textbf{df} = \textbf{10} \ (\textbf{P} = \textbf{2} \\ \textbf{2}  \textbf{83} \\ \textbf{3355} \\ \textbf{133} \\ \textbf{53}  \textbf{53}  \textbf{446} \\ \textbf{1}  \textbf{22} \\ \textbf{6}  \textbf{175} \\ \textbf{139}  \textbf{1593} \\ \textbf{53}  \textbf{53} \\ \textbf{46} \\ \textbf{1}  \textbf{22} \\ \textbf{5}  \textbf{83} \\ \textbf{5}  \textbf{73} \\ \textbf{2392} \\ \textbf{209} \\ \textbf{0.79}; \textbf{Chi^{2}} = \textbf{38} \\ \textbf{39}  \textbf{5}  \textbf{3} \\ \textbf{5} \\ \textbf{73} \\ \textbf{299} \\ \textbf{1} \end{array}$	20 20 20 20 20 20 25 25 20 20 20 20 20 20 20 20 20 20	2000 265 20 161 2948 a 49% d Total 111 207 69 200 265 20 161 87 309 200 265 20 161 87 309 200 0% 4 5 6 87 309 200 5 20 101 117 177 69 200 205 20 101 117 177 69 200 205 20 101 177 69 200 205 20 101 177 69 200 205 205 101 177 69 200 205 205 101 177 69 200 205 205 101 177 69 200 205 205 101 177 69 200 205 205 101 177 69 200 205 205 101 177 69 200 205 207 101 107 205 207 101 107 205 200 101 177 69 200 205 207 101 177 69 200 205 207 101 177 69 200 205 207 101 177 69 200 205 207 101 177 69 200 205 207 101 177 69 200 205 207 107 177 69 200 205 207 107 177 177 69 200 205 207 177 177 177 69 200 205 207 207 207 207 207 207 207 207	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.4% 5.9% 4.5% 38.9% 4.5% 38.9% 1.7% 1.5% 1.7% 1.5% 1.7% 1.5% 100.0% 0001); P =	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.65 [0.32, 1.01] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.24, 1.38] 1.24 [0.24, 7.48] 0.58 [0.59, 1.32] 1.24 [0.24, 7.48] 0.50 [0.04, 1.53] 1.10 [0.64, 1.87] 0.66 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02] 0.dds Ratio M-H. Random. 95% CC 0.59 [0.24, 1.67] 1.03 [0.80, 1.33] 1.58 [0.98, 2.54] 0.43 [0.04, 5.13] 0.56 [0.17, 1.81] 0.53 [0.23, 1.21] 87%	0.01	Odds Ratio M-H. Fixed, 95% Cl Odds Ratio M-H. Fixed, 95% Cl Odds Ratio M-H. Random, 95% Cl Odds Ratio M-H. Random, 95% Cl Odds Ratio
E	2012 LIPSIA 2013 ELISA3 2015 Liu et al. 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ELISA 2003 ELISA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2019 ZIISA 2010 Zhang et al. 2015 SISCA Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 1 Test for overall effect: ReDeated Revascul <u>Study or Subgroup</u> 2009 ABOARD 2009 ABOARD 2009 ABOARD 2009 ABOARD 2009 ABOARD 2009 ABOARD 2009 ABOARD 2009 IMACS 2010 Zhang et al. 2015 Liu et al. 2015 SISCA 2016 OPTIMA Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	$\begin{array}{c} \text{20} & \text{-}\text{+}\text{0}\\ 0 & 200\\ 0 & 200\\ 20 & 269\\ 3 & 22\\ 16 & 162\\ \textbf{3} & 122\\ \textbf{1} & \textbf{6} & 162\\ \textbf{2} & \textbf{5} & \textbf{1} & \textbf{6} & \textbf{7}\\ \textbf{2} & \textbf{6} & \textbf{2} & \textbf{1} & \textbf{7}\\ \textbf{2} & \textbf{6} & \textbf{2} & \textbf{1} & \textbf{7}\\ \textbf{2} & \textbf{6} & \textbf{2} & \textbf{1} & \textbf{7}\\ \textbf{2} & \textbf{6} & \textbf{1} & \textbf{7} & \textbf{7}\\ \textbf{5} & \textbf{3} & \textbf{7} & \textbf{3}\\ \textbf{4} & \textbf{9} & \textbf{1593}\\ \textbf{3} & \textbf{446} & \textbf{1} & 200\\ \textbf{32} & 269\\ 0 & 0 & 22\\ \textbf{1} & 162\\ \textbf{2} & \textbf{83}\\ \textbf{3} & \textbf{346} & \textbf{1} & \textbf{200}\\ \textbf{32} & 269\\ 0 & 0 & 22\\ \textbf{1} & 162\\ \textbf{2} & \textbf{83}\\ \textbf{3335}\\ \textbf{5} & \textbf{73}\\ \textbf{8} & \textbf{77}, & \textbf{1} & \textbf{6} & 10\\ \textbf{7} & \textbf{6} & 10\\ \textbf{7} & \textbf{7} & \textbf{1} & \textbf{9}\\ \textbf{8} & \textbf{7}, & \textbf{1} & \textbf{1} & \textbf{1} & \textbf{200}\\ \textbf{32} & 269\\ \textbf{0} & \textbf{1} & \textbf{200}\\ \textbf{335} & \textbf{53} & \textbf{466}\\ \textbf{1} & 20\\ \textbf{2} & \textbf{6} & 175\\ \textbf{5} & \textbf{3} & \textbf{5} & \textbf{5}\\ \textbf{5} & \textbf{73}\\ \textbf{5} & \textbf{5} & \textbf{73}\\ \textbf{2392}\\ \textbf{2099}\\ \textbf{0} & \textbf{79}; & \textbf{Ch}^{\text{P}} & \textbf{38}, \textbf{9}\\ \textbf{2} & \textbf{1} & \textbf{501} & \textbf{53}\\ \textbf{5} & \textbf{73}\\ \textbf{2392}\\ \textbf{2099}\\ \textbf{0} & \textbf{79}; & \textbf{Ch}^{\text{P}} & \textbf{38}, \textbf{9}\\ \textbf{2} & \textbf{1} & \textbf{501} & \textbf{53}\\ \textbf{5} & \textbf{73}\\ \textbf{2392}\\ \textbf{2} & \textbf{1} & \textbf{501} & \textbf{53}\\ \textbf{5} & \textbf{73}\\ \textbf{2} & \textbf{292}\\ \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} \\ \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} \\ \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} \\ \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} \\ \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} \\ \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} \\ \textbf{1} & \textbf{1} & \textbf{1} \\ \textbf{1} & \textbf{1} & \textbf{1} \\ \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} \\ \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} \\ \textbf{1} & \textbf{1} & \textbf{1} \\ \textbf{1} & \textbf{1} & \textbf{1} \\ \textbf{1} & \textbf{1} & \textbf{1} & \textbf{1} \\ \textbf$	200 33 30 252 252 20.05);   <sup>3</sup> 0001) <b>delaye</b> <b>Events</b> 15 8 12 6 50 2 2 2 9 5 5 1 135 0.55);   <sup>3</sup> 2 2 5 5 1 135 0.55;   <sup>3</sup> 2 2 9 5 5 1 135 0.55;   <sup>3</sup> 4 h) <b>delaye</b> 2 2 9 5 5 1 1 35 0.55;   <sup>3</sup> 3 4 135 0.55;   <sup>3</sup> 3 4 135 0.55;   <sup>3</sup> 3 5 5 1 1 3 5 5 1 1 3 5 5 1 1 3 5 5 1 1 3 5 5 1 1 3 5 5 1 1 3 5 5 1 1 3 5 5 1 1 3 5 5 5 1 1 3 5 5 5 1 1 3 5 5 5 1 1 3 5 5 5 1 1 3 5 5 5 1 1 3 5 5 5 1 1 3 5 5 5 1 1 3 5 5 5 1 1 3 5 5 5 1 1 3 5 5 5 1 1 3 5 5 5 1 1 3 5 5 5 1 1 3 5 5 5 1 1 2 2 2 9 5 5 5 1 1 1 2 2 2 9 5 5 5 1 1 1 2 2 2 9 5 5 5 1 1 1 2 2 2 9 5 5 5 1 1 2 2 2 9 5 5 5 1 1 2 2 2 9 5 5 5 1 1 2 2 2 9 5 5 5 1 1 2 2 2 9 5 5 5 1 2 2 2 9 5 5 5 1 1 2 2 2 9 5 5 5 1 1 2 2 2 9 5 5 5 1 2 2 2 9 5 5 5 1 1 2 2 2 9 5 5 5 1 1 2 2 2 9 5 5 5 1 2 2 2 9 5 5 5 1 2 1 2 1 2 9 5 5 5 1 2 2 2 9 5 5 5 1 2 2 2 9 5 5 5 1 2 1 2 9 5 5 5 1 2 2 9 5 5 5 1 2 1 2 9 5 5 1 2 1 2 1 1 2 1 1 1 1 2 1 1 1 1 1 2 1 1 1 1 1 2 1 1 1 1 1 1 1 1 2 1	2000 265 20 161 2948 d Total 111 107 177 69 200 207 177 69 200 161 87 3104 10% 117 69 200 161 207 205 200 161 207 101 207 101 207 101 207 101 207 101 207 101 207 101 207 101 207 101 207 101 207 101 207 101 207 101 207 101 207 101 207 107 107 107 107 107 107 107 1	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0% 1.7% 1.5% 8.7% 4.5% 1.7% 1.5% 1.7% 1.5% 1.7% 1.5% 1.7% 1.5% 1.7% 1.5% 1.6% 100.0%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.65 [0.40, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.50 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.66 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 23.87] 0.79 [0.61, 1.02] 0.43 [0.21, 1.67] 0.59 [0.21, 1.67] 1.03 [0.80, 1.33] 1.58 [0.98, 2.54] 0.43 [0.04, 2.53] 0.56 [0.17, 1.81] 0.53 [0.23, 1.21] 87%	0.01	Odds Ratio M-H. Fixed. 95% Cl 0.1 1 00 Favours early Favours delayed 0.1 1 0 100 Favours early Favours delayed 0.1 1 0 100 Favours early Favours delayed
E	2012 LIPSIA 2013 ELISA3 2013 ELISA3 2015 ELIDA3 2015 RIDDLE Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect: Major Bleeding (< <u>Study or Subgroup</u> 2003 ELISA 2003 ELISA 2003 ELISA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMA 2009 OPTIMACS 2010 Zhang et al. 2015 RIDDLE 2015 RIDDLE 2015 RIDDLE 2015 RISCA Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = : Test for overall effect: 2010 Zhang et al. 2015 SISCA 2010 Jhang et al. 2015 SISCA 2016 OPTIMA Total (95% CI) Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect: :	$\begin{array}{c} \text{20} & \text{-}4\text{-}0\\ 0 & 200\\ 20 & 269\\ 3 & 22\\ 16 & 162\\ \textbf{3779}\\ \textbf{142}\\ \textbf{15.72}, df = 8 (P = 2\\ \textbf{2} = 6.21 (P < 0.0\\ (24h)\\ \textbf{early}\\ \textbf{early}\\ \textbf{Events}  \textbf{Total}\\ 9 & 109\\ 6 & 203\\ 7 & 175\\ 3 & 73\\ 49 & 1593\\ 3 & 446\\ 1 & 200\\ 32 & 269\\ 0 & 22\\ 1 & 162\\ 2 & 83\\ \textbf{33335}\\ \textbf{3334}\\ \textbf{466}\\ 1 & 200\\ 32 & 269\\ 0 & 022\\ 1 & 162\\ 2 & 83\\ \textbf{3335}\\ \textbf{3335}\\ \textbf{33466}\\ 1 & 200\\ 2 & 83\\ \textbf{3335}\\ 3335$	20 20 33 100 27 252 20.05);   <sup>2</sup> = 0001) <b>delaye</b> <b>Events</b> 15 8 12 6 50 2 2 9 9 5 5 1 1 135 0.55);   <sup>2</sup> = 7 1 135 0.55);   <sup>2</sup> = 7 1 135 0.55);   <sup>2</sup> = 7 1 <b>delaye</b> <b>Events</b> 1 <b>delaye</b> <b>Events</b> 1 <b>1</b> <b>1</b> <b>1</b> <b>1</b> <b>1</b> <b>1</b> <b>1</b>	2000 265 20 161 2948 d Total 111 207 117 69 200 161 1438 369 200 161 1438 369 200 161 438 369 200 161 438 369 200 69 210 69 210 69 210 69 210 69 210 69 210 69 210 200 200 200 200 200 200 200	8.6% 12.9% 3.8% 10.3% 100.0% 100.0% 100.0% 4.5% 38.9% 4.5% 38.9% 4.5% 3.8% 0.7% 100.0% 10.0% Veight 18.7% 22.2% 7.5% 17.0% 15.5% 10.6% 10.6%	0.02 [0.00, 0.37] 0.56 [0.32, 1.01] 0.65 [0.40, 0.71] 0.54 [0.28, 1.05] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.50 [0.40, 0.62] 0.58 [0.24, 1.38] 0.76 [0.26, 2.22] 0.57 [0.22, 1.49] 0.45 [0.11, 1.87] 0.88 [0.59, 1.32] 1.24 [0.21, 7.48] 0.50 [0.04, 5.53] 1.10 [0.64, 1.87] 0.06 [0.00, 1.22] 0.19 [0.02, 1.68] 2.12 [0.19, 2.387] 0.79 [0.61, 1.02] Odds Ratio MH. Random. 95% C 0.59 [0.21, 1.67] 1.03 [0.80, 1.33] 1.58 [0.89, 2.54] 0.43 [0.04, 5.13] 0.59 [0.21, 1.67] 1.03 [0.80, 2.13] 0.59 [0.21, 1.67] 1.03 [0.80, 2.54] 0.43 [0.04, 5.13] 0.55 [0.17, 1.81] 0.53 [0.23, 1.21]	0.01	Odds Ratio M-H, Fixed, 95% Cl 0.1 100 Favours delayed 0.1 100 M-H, Fixed, 95% Cl 0.1 100 Favours delayed 0.1 100 0.1 100 Favours delayed 0.1 100 Favours delayed 0.1 100 0.1 00 0.1 00 0.1 00 0.0 00 0

FIGURE 5 | Forest plots comparing outcomes between early (< 24 h) invasive group and delayed invasive group. (A) Mortality, (B) myocardial infarction, (C) refractory lschemia, (D) major bleeding, and (E) repeated revascularization.

		immed	iate	delay	ed		Odds Ratio	Odds Ratio
Ŀ	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
	2009 ABOARD	5	175	2	177	6.8%	2.57 [0.49, 13.45]	
	2012 LIPSIA	9	200	13	200	43.4%	0.68 [0.28, 1.62]	
	2015 RIDDLE	8	162	9	161	30.0%	0.88 [0.33, 2.33]	
	2016 OPTIMA	6	73	6	69	19.8%	0.94 [0.29, 3.07]	
	Total (95% CI)		610		607	100.0%	0.92 [0.54, 1.56]	<b>•</b>
	Total events	28		30				
	Heterogeneity: Chi <sup>2</sup> = 1	1.97, df =	3 (P = 0	0.58); l <sup>2</sup> =	0%			0.01 0.1 1 10 1
	l est for overall effect: A	Z = 0.32 (	P = 0.7	5)				Favours immediate Favours delayed
В	Myocardial Infar	ction (	<2h)					
		immedia	te	delayed	I		Odds Ratio	Odds Ratio
_	Study or Subgroup	Events	Total	Events	otal \	Veight	M-H, Random, 95% C	I M-H, Random, 95% CI
	2009 ABOARD	16	175	8	177	27.4%	2.13 [0.89, 5.10]	
	2012 LIPSIA	33	200	16	200	29.1%	2.27 [1.21, 4.28]	
	2015 RIDDLE	5	162	22	161	26.4%	0.20 [0.07, 0.55]	
	2016 OPTIMA	8	73	1	69	17.2%	8.37 [1.02, 68.79]	
	Total (95% CI)		610		<b>607</b> 1	00.0%	1.47 [0.40, 5.40]	
	Total events	62		47				
	Heterogeneity: Tau <sup>2</sup> = 1.	41; Chi <sup>2</sup> =	= 20.52,	df = 3 (P	= 0.000	01); l <sup>2</sup> = 85	5%	
	Test for overall effect: Z	= 0.58 (P	= 0.56	)				U.UI U.I 1 10 10
~	D - Course to any Toolo		(21.)					Favours immediate Favours delayed
	Refractory Ische	imia (<	<2n)					
	fans de la servit	immedia	te	delayed	1		Odds Ratio	Odds Ratio
_	Study or Subgroup	Events	Total	Events	otal \	Veight	<u>M-H, Random, 95% C</u>	I M-H, Random, 95% Cl
	2009 ABOARD	21	175	33	177	46.4%	0.60 [0.33, 1.08]	
	2012 LIPSIA	0	200	20	200	9.2%	0.02 [0.00, 0.37]	·
	2015 RIDDLE	16	162	27	161	44.4%	0.54 [0.28, 1.05]	
	Total (95% CI)		537		538 1	00.0%	0.42 [0.17, 1.07]	
	Total events	37		80				
	Heterogeneity: Tau <sup>2</sup> = 0.	.40; Chi² =	= 6.16, 0	df = 2 (P =	= 0.05);	l² = 68%		
	Test for overall effect: Z	= 1.81 (P	= 0.07)	)				Equours immediate Equours delayed
D	Major Bleeding	(<2h)						Favours inimediate Favours delayed
	, 0	immedi	iate	delav	he		Odds Ratio	Odds Ratio
	Study or Subaroup	Events	Total	Events	Total	Weight	M-H Fixed 95% Cl	M-H Fixed 95% Cl
-		7	175	12	177	17 1%	0.57 [0.22, 1.40]	
		3	73	6	60	2/ 30/	0.37 [0.22, 1.43] 0.45 [0.11, 1.87]	
	2009 OF TIMA	1	200	2	200	24.J /0 8 20/	0.45 [0.11, 1.07]	
		1	160	2	161	20 50/	0.00 [0.04, 0.03]	
	2013 RIDDLE	1	102	э	101	20.5%	0.19 [0.02, 1.68]	
	Total (95% CI)		610		607	100.0%	0.46 [0.23, 0.93]	
	I otal events	12		25				
	Heterogeneity: Chi <sup>2</sup> = 0	.82, df = :	3 (P = (	).84); l <sup>2</sup> =	0%			0.01 0.1 1 10 1
	Test for overall effect: 2	z = 2.17 (l	P = 0.0	3)				Favours immediate Favours delayed
		culariza	tion	(<2h)	a al		Odda Datia	Odda Datia
E	Repeated Revase	iner and a second	iate	delay	ea Tetel	Mainht	Udds Ratio	Udds Katio
E	Repeated Revaso	immed	Tetel	Events	Iotal	er on	WI-FI, FIXED, 95% CI	
E	Repeated Revaso	immed Events	Total			55.6%	0.59 [0.21, 1.67]	
Ξ.	Repeated Revaso	immed Events 6	Total 175	10	177		A FA 16	
E	Repeated Revaso Study or Subgroup 2009 ABOARD 2016 OPTIMA	immed Events 6 5	<u>Total</u> 175 73	10 8	177 69	44.4%	0.56 [0.17, 1.81]	-
E .	Repeated Revaso Study or Subgroup 2009 ABOARD 2016 OPTIMA Total (95% CI)	immed Events 6 5	Total 175 73 248	10 8	177 69 <b>246</b>	44.4% 100.0%	0.56 [0.17, 1.81] <b>0.58 [0.27, 1.26]</b>	•
E .	Repeated Revaso <u>Study or Subgroup</u> 2009 ABOARD 2016 OPTIMA Total (95% CI) Total events	immed Events 6 5 11	Total 175 73 248	10 8 18	177 69 <b>246</b>	44.4% 100.0%	0.56 [0.17, 1.81] 0.58 [0.27, 1.26]	
E .	Repeated Revaso Study or Subgroup 2009 ABOARD 2016 OPTIMA Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = C	immed <u>Events</u> 6 5 11 0.00, df =	<u>Total</u> 175 73 <b>248</b> 1 (P = 0	10 8 18 0.94); I <sup>2</sup> =	177 69 <b>246</b> 0%	44.4% 100.0%	0.56 [0.17, 1.81] 0.58 [0.27, 1.26]	
E .	Repeated Revaso Study or Subgroup 2009 ABOARD 2016 OPTIMA Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 0 Test for overall effect: 2	immed <u>Events</u> 6 5 11 0.00, df = Z = 1.38 (	<u>Total</u> 175 73 <b>248</b> 1 (P = 0 P = 0.1	10 8 18 0.94); I <sup>2</sup> = 7)	177 69 <b>246</b> 0%	44.4% 100.0%	0.56 [0.17, 1.81] 0.58 [0.27, 1.26]	0.01 0.1 1 10 1 Eavours immediate Eavours delayed
E	Repeated Revaso Study or Subgroup 2009 ABOARD 2016 OPTIMA Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = 0 Test for overall effect: 2	immed <u>Events</u> 6 5 11 0.00, df = Z = 1.38 (	<u>Total</u> 175 73 <b>248</b> 1 (P = 0 P = 0.1	10 8 18 0.94); I <sup>2</sup> = 7)	177 69 <b>246</b> 0%	44.4%	0.56 [0.17, 1.81] 0.58 [0.27, 1.26]	0.01 0.1 1 10 1 Favours immediate Favours delayed

no significant interaction between the two groups denoting pre-specified subgroups and the assignment to immediate vs. delayed invasive strategy on the primary endpoint (Milosevic

et al., 2016). However, in the TIMACS trial, early invasive strategy did not differ greatly from delayed intervention in preventing the primary outcome, but in high-risk patients, it

,	immediate	(<6h)	delaye	ed		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
2003 ISAR-COOL	6	203	8	207	23.3%	0.76 [0.26, 2.22]	
2009 ABOARD	7	175	12	177	34.7%	0.57 [0.22, 1.49]	
2009 OPTIMA	3	73	6	69	17.9%	0.45 [0.11, 1.87]	
2012 LIPSIA	1	200	2	200	6.0%	0.50 [0.04, 5.53]	
2015 RIDDLE	1	162	5	161	15.1%	0.19 [0.02, 1.68]	
2015 SISCA	2	83	1	87	2.9%	2.12 [0.19, 23.87]	
Total (95% CI)		896		901	100.0%	0.58 [0.33, 1.01]	•
Total events	20		34				
Heterogeneity: Chi <sup>2</sup> = 2		P = 0.78	); l² = 0%				
Test for overall effect: 2	Z = 1.92 (P =	• 0.06)					Favours immediate Favours delayed

FIGURE 7 | Forest plot comparing major bleeding between immediate (<6 h) invasive group and delayed invasive group.



did reduce the rate of the composite secondary outcome of death, MI, or refractory ischemia and was superior to delayed intervention (Mehta et al., 2009). Current recommendations from international guidelines for NSTE-ACS are based on the subgroup analysis of the TIMACS trial. However, the only two articles for classification with a GRACE risk score led to different conclusions. Further large-scale, high-quality RCTs with adequate follow-up duration as well as risk stratification analysis are warranted.

# **Definition of New MI**

In NSTE-ACS patients, refractory ischemia has been associated with a more than 4-fold risk of developing MI (Mehta et al., 2009), however, the reduction of refractory ischemia in early intervention group was not translated into lower MI rates and the heterogeneity was high ( $I^2 = 75\%$  and  $I^2 = 85\%$  in **Figures 5B**, **6B**, respectively), it was probably because the definition of new MI was not consistent among these studies. In RCTs of past few years, the definition was relatively more reliable. For example,

in RIDDLE, the definition of new MI was associated with the time period after randomization (Mehta et al., 2009). But in some studies such as OPTIMA, the definition solely based on the rise in CK-MB, this non-standard definition may have led to overestimation of the new MI rate. If different definitions were used on the same set of patients, the rates of MI reported would be significantly different, therefore, the benefit of early intervention in NSTE-ACS patients might be underestimated.

### Limitations

On a whole, the overall sample size is small, especially in the comparison between immediate and delayed intervention groups; although immediate intervention showed a benefit in decreasing of major bleeding, there were only four included studies and thus the results should be treated with caution. Further data from high-quality RCTs are required to reach reliable conclusions. Besides, the event rates was low and a single trial (TIMACS) contributed to most events. Furthermore, we found that the heterogeneity in the timing of intervention and in patient risk profiles. Besides, most of the follow-up periods of these RCTs were <6 months, only one study (OPTIMA) conducted a follow-up to 5 years, more RCTs with long term follow-up were still warranted. Nevertheless, this study is the largest pooled data sample of RCTs on early/immediate vs. delayed invasive intervention in NSTE-ACS populations and offers basic knowledge for future clinical trials.

# CONCLUSIONS

For the first time, it was found that compared with a delayed invasive strategy, an early invasive strategy might reduce mortality rate and the risk of refractory ischemia. However, as the

# REFERENCES

- Abbas, A. E., Brodie, B., Dixon, S., Marsalese, D., Brewington, S., O'Neill, W. W., et al. (2005). Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction. *Am. J. Cardiol.* 96, 173–176. doi: 10.1016/j.amjcard.2005.03.038
- Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Jr. et al. (2013). 2012 ACCF/AHA focused update incorporated Into the ACCF/AHA 2007 guidelines for the management of patients with unstable Angina/Non-ST-elevation myocardial Infarction: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am. Coll. Cardiol. 61, 179–347. doi: 10.1016/j.jacc.2013.01.014
- Badings, E. A., The, S. H., Dambrink, J. H., van Wijngaarden, J., Tjeerdsma, G., Rasoul, S., et al. (2013). Early or late intervention in high-risk non-ST-elevation acute coronary syndromes: results of the ELISA-3 trial. *EuroIntervention*. 9, 54–61. doi: 10.4244/EIJV9I1A9
- Fox, K. A., Clayton, T. C., Damman, P., Pocock, S. J., de Winter, R. J., Tijssen, J. G., et al. (2010). Long-term outcome of a routine vs. selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome. J. Am. Coll Cardiol. 55, 2435–2445. doi: 10.1016/j.jacc.2010.03.007
- Hamm, C. W., Bassand, J. P., Agewall, S., Bax, J., Boersma, E., Bueno, H., et al. (2011). ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur. Heart J.* 32, 2999–3054. doi: 10.1093/eurheartj/ehr236

upper limit value of CI was very close to 1 and *P* was the critical value, and the result of TSA indicated that the meta-analysis may result in false positive. Meanwhile, immediate invasive therapy could reduce the risk of major bleeding. To achieve definitive conclusion, RCTs of large sample size, long-term follow-up and clinically relevant definition of periprocedural MI are warranted.

# **AUTHOR CONTRIBUTIONS**

YX and XX: defined the research theme; YL, WC, ZZ, YG, and DH: designed the methods and analyzed the data; HS, YL, and YX: interpreted the results; YX and YL: wrote the manuscript; All authors discussed the results and commented on the manuscript.

## ACKNOWLEDGMENTS

The current work was supported by the National Natural Science Foundation Project of China (Grant Nos. 81001514, 81373835, and 81430098), the Fundamental Research Funds for the Central Public Welfare Research Institutes (Grant No. ZZ070802), National high-level talent special support plan (No. W02020052), and the National clinical research base of TCM project of the State Administration of traditional Chinese medicine (JDZX2015007).

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphys. 2017.00952/full#supplementary-material

- Higgins, J. P., and Green, D. (2011). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Bristol, UK: The Cochrane Collaboration [updated March 2011].
- Honnig, M. R., Doust, J. A., and Aroney, C. N. (2006). Early invasive vs. conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era, *Cochrane Database Syst. Rev.* 3:CD004845. doi: 10.1002/14651858.CD004815.pub2
- IDEAL NSTEMI (2012). ImmeDiate vs. EArLy Invasive Approach in Non-ST-Elevation Myocardial Infarction (IDEAL NSTEMI) Trial. Available online at: http://clinicaltrials.gov/ct2/show/NCT00954668 (Accessed May 12, 2012).
- Jobs, A., Mehta, S. R., Montalescot, G., Vicaut, E., Van't Hof, A. W. J., Badings, E. A., et al. (2017). Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials. *Lancet* 390, 737–746. doi: 10.1016/S0140-6736(17)31490-3
- Kwok, C. S., Khan, M. A., Rao, S. V., Kinnaird, T., Sperrin, M., Buchan, I., et al. (2015). Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis. *Circ. Cardiovasc. Interv.* 8:e001645. doi: 10.1161/CIRCINTERVENTIONS.114. 001645.
- Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., et al. (2011). ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. *Circulation* 124, 2574–609. doi: 10.1161/CIR.0b013e3182 3a5596

- Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *Ann. Intern. Med.* 151, 65–94. doi: 10.7326/0003-4819-151-4-200908180-00136
- Liu, Z., Zhao, L., Li, Y., Wang, Z., Liu, L., and Zhang, F. (2015). Evaluation of early interventional treatment opportunity of the elderly & high-risk patients with non-ST segment elevation acute myocardial infarction. *Pak. J. Med. Sci.* 31, 1053–1056. doi: 10.12669/pjms.315.7881
- Mehta, S. R., Cannon, C. P., Fox, K. A., Wallentin, L., Boden, W. E., Spacek, R., et al. (2005). Routine vs. selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. *JAMA* 293, 2908–2917. doi: 10.1001/jama.293.23.2908
- Mehta, S. R., Granger, C. B., Boden, W. E., Steg, P. G., Bassand, J.-P., Faxon, D. P., et al. (2009). Early vs. delayed invasive intervention in acute coronary syndromes. N. Engl. J. Med. 360, 2165–2175. doi: 10.1056/NEJMoa0807986
- Milasinovic, D., Milosevic, A., Marinkovic, J., Vukcevic, V., Ristic, A., Asanin, M., et al. (2015). Timing of invasive strategy in NSTE-ACS patients and effect on clinical outcomes: a systematic review and metaanalysis of randomized controlled trials. *Atherosclerosis* 241, 48–54. doi: 10.1016/j.atherosclerosis.2015.04.808
- Milosevic, A., Vasiljevic-Pokrajcic, Z., Milasinovic, D., Vukcevic, V., Asanin, M., and Stankovic, G. (2016). Immediate vs. delayed invasive intervention for Non-ST-segment elevation myocardial infraction patients: the RIDDLE-NSTEMI study. J. Am. Coll. Cardiol. 9, 541–549. doi: 10.1016/j.jcin.2015.11.018
- Montalescot, G., Cayla, G., Collet, J. P., Elhadad, S., Beygui, F., Le Breton, H., et al. (2009). Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. *JAMA* 302, 947–954. doi: 10.1001/jama.2009.1267
- Navarese, E. P., De Servi, S., Gibson, C. M., Buffon, A., Castriota, F., Kubica, J., et al. (2011). Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: a meta-analysis of randomized studies. Q. J. Med. 104, 193–200. doi: 10.1093/qjmed/hcq258
- Navarese, E. P., Gurbel, P. A., Andreotti, F., Tantry, U., Jeong, Y. H., Kozinski, M., et al. (2013). Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. *Ann. Intern. Med.* 158, 261–270. doi: 10.7326/0003-4819-158-4-201302190-00006
- Neumann, F. J., Kastrati, A., Pogatsa-Murray, G., Mehilli, J., Bollwein, H., Bestehorn, H. P., et al. (2003). Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. *JAMA* 290, 1593–1599. doi: 10.1001/jama.290.12.1593
- Nikolsky, E., Mehran, R., and Stone, G. W. (2009). Gastrointestinal bleeding in percutaneous coronary intervention and acute coronary syndromes. *Am. J. Cardiol.* 104(Suppl. 5), 22C–29C. doi: 10.1016/j.amjcard.2009.06.022
- Oosterwerff, E. F., Fagel, N. D., Slagboom, T., Tijssen, J. G. P., Herrman, J. P., Smits, P. C., et al. (2016). Impact of percutaneous coronary intervention timing on 5-year outcome in patients with non-ST-segment elevation acute coronary syndromes. the 'wait a day' approach might be safer. *Neth. Heart J.* 24, 173–180. doi: 10.1007/s12471-016-0803-0
- Rajpurohit, N., Garg, N., Garg, R., Choudhary, A., Fresen J., Boren S., et al. (2013). Early vs. delayed percutaneous coronary intervention for patients

with non-ST segment elevation acute coronary syndrome: a meta-analysis of randomized controlled clinical trials. *Catheter Cardiovasc. Interv.* 81, 223–231. doi: 10.1002/ccd.24439

- Reuter, P. G., Rouchy, C., Cattan, S., Benamer, H., Jullien, T., Beruben, A., et al. (2015). Early invasive strategy in high-risk acute coronary syndrome without ST-segment elevation. the sisca randomized trial. *Int. J. Cardiol.* 182, 414–418. doi: 10.1016/j.ijcard.2014.12.089
- Riezebos, R. K., Ronner, E., Ter Bals, E., Slagboom, T., Smits, P. C., ten Berg, J. M., et al. (2009). Immediate vs. deferred coronary angioplasty in non st-segment elevation acute coronary syndromes. *Heart* 95, 807–812. doi: 10.1136/hrt.2008.154815
- Sciahbasi, A., Madonna, M., De Vita, M., Agati, L., Scioli, R., Summaria, F., et al. (2010). Comparison of immediate vs early invasive strategy in patients with first acute Non–ST-elevation myocardial infarction. *Clin. Cardiol.* 33, 650–655. doi: 10.1002/clc.20785
- Tekin, K., Cagliyan, C. E., Tanboga, I. H., Balli, M., Uysal, O. K., Ozkan, B., et al. (2013). Influence of the timing of percutaneous coronary intervention on clinical outcomes in Non-ST-elevation myocardial infarction, Korean. *Circ. J.* 43, 725–730. doi: 10.4070/kcj.2013.43. 11.725
- Tetsuya, T., Watanabe, T., Nadatani, Y., Otani, K., Machida, H., Okazaki, H., et al. (2011). Gastrointestinal bleeding after percutaneous coronary intervention. *Digestion* 83, 153–160. doi: 10.1159/0003 21813
- Thiele, H., Rach, J., Klein, N., Pfeiffer, D., Hartmann, A., Hambrecht, R., et al. (2012). Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: the Leipzig immediate vs. early and late percutaneous coronary intervention trial in NSTEMI (LIPSIANSTEMI Trial). *Eur. Heart J.* 33, 2035–2043. doi: 10.1093/eurheartj/ehr418
- van't Hof, A. W., de Vries, S. T., Dambrink, J.-H. E., Miedema, K., Suryapranata, H., Hoorntje, J. C. A. et al. (2003). A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the early or late intervention in unstable angina (ELISA) pilot study. 2b/3a upstream therapy and acute coronary syndromes. *Eur. Heart J.* 24, 1401–1405. doi: 10.1016/S0195-668X(03)00259-8
- Zhang, J., Qiao, S. B., and Zhu, J. (2010). Chinese cooperative group of the timing of intervention in acute coronary syndrome. [outcome of patients with non-ST segment elevation acute coronary syndrome undergoing early or delayed intervention]. Zhonghua Xin Xue Guan Bing Za Zhi. 38, 865–869. doi: 10.3760/ cma.j.issn.0253-3758.2010.10.001

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Li, Zhang, Xiong, Cho, Hu, Gao, Shang and Xing. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.